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Abstract 
Current Good Manufacturing Practices (cGMP' s) were developed to keep the 
public safe and ensure quality products. Technological evolution of the industry 
resulted in cGMP requirements which could not keep pace, and ultimately had a 
restrictive effect on daily operations and process improvements for pharmaceutical 
manufacturers. In response, the FDA has recently released new Guidances for 
Industry, PAT-A Framework for Innovative Pharmaceutical Development, 
Manufacturing, and Quality Assurance and Pharmaceutical cGMP's for the 21st 
Century-A Risk-Based Approach, to encourage innovation in the pharmaceutical 
industry. The current focus is to understand the product, the manufacturing process 
and operations rather than the previous focus on product testing and release. Other 
industries have developed innovative approaches to competitive improvement and it 
is important to learn from their successes and failures . 
The aim of this study is to identify critical areas for improvement in current 
pharmaceutical manufacturing practices and to explore solutions to these problems 
using principles found outside of the pharmaceutical industry. A facility producing 
pharmaceutical products under cGMP's will be evaluated to gain a "baseline" 
understanding of current manufacturing practices. Critical and problematic areas 
will be identified as well as potential opportunities to incorporate external industry 
practices, with a focus on the Toyota Production System®, to improve the 
manufacturing process. 
A ProModel® simulation was developed in as a proof of concept to evaluate 
proposed improvements to the system. This simulation was run with a number of 
theoretical changes to the scenario to evaluate the effects and interactions of the 
proposed improvements. These areas of improvements include: Shrinking traditional 
batching rules to create a more semi continuous production system, cross training 
personnel on equipment and responsibilities, and the addition of parallel machines at 
the equipment bottleneck. 
Results from the simulation experimentations indicated that significant 
improvements to product throughput time can be achieved. While all three 
individual factors studied were found to be significant, the greatest gains were 
achieved using a combination of batch rule changes and cross training of personnel. 
Changing the batching rules was found to have the greatest effect on reducing 
throughput times, due to the drastic reduction of time spent waiting to batch in the 
system. Cross training resulted in increased capacity in the bottleneck machine with 
availability during all hours of operation. While parallel machining did achieve 
improved throughput times when compared to the current state of the system, the 
additional machine was not justified when compared with the scenario yielding 
superior results. 
Lean manufacturing and other alternative techniques should be explored in 
the pharmaceutical industry to improve current systems and utilized early in the 
development of new systems. This case study represents a number of possible 
opportunities for specific areas of improvement as well as suggesting an overall 
change in manufacturing mindset. The pharmaceutical industry can learn a great 
deal from outside industries where competitiveness is required to ensure solvency. 
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Chapter 1 
1.0 Introduction 
Chapter one aims to orient the reader with a brief history of both general 
manufacturing and pharmaceutical manufacturing. The history discussed is not 
intended as a comprehensive review of manufacturing, rather it will give the reader 
perspective with regard to the origins and ongoing evolution of the state of 
manufacturing. This chapter will also describe the general study objectives of this 
thesis. 
1.1 Brief History of Manufacturing 
In 1776 Adam Smith published "An Inquiry into the Nature and Causes of 
the Wealth of Nations" and introduced the concept of the division of labor. Smith 
felt that by dividing complex jobs which were previously performed by skilled 
artisans (carpenters, smiths, etc .. . ) into simplified tasks, greater levels of efficiency 
could be achieved. His experiments first assessed the production of metal pins by 
unskilled laborers using traditional craft methods, which required all aspects of 
manufacturing. He then compared these laborers to a group which had the 
manufacturing process divided into one or a few simple tasks. Each laborer was 
responsible for their individual area of pin manufacturing and he found a large 
increase in productivity. He attributed the increased output to three reasons: 1. An 
increase in the operator's dexterity due to simple and repetitive tasks. 2. 
Minimization of travel time because the product moved and the people did not and 3. 
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Tools used in the manufacturing can be optimized based on the operator's superior 
knowledge of the process (Smith, 1776). 
The introduction of interchangeable parts for the manufacturing of muskets 
by Honore Blanc in the late 1700's also signaled an important milestone in the 
evolution of manufacturing. By creating interchangeable parts through the 
standardization of templates and equipment, he replaced artisan craftsman and 
enabled unskilled laborers to be trained with manufacturing tools to generate greater 
production numbers at lower costs. This new method was adopted in many other 
industries throughout the world and facilitated the rapid growth of mass production 
(Gillespie, 1998; Hopp, 2001). 
In 1913, Henry Ford introduced a continuously moving assembly line which 
allowed workers to remain in their workstations to add parts to cars as they passed 
by. Parts were supplied to workers through conveyors and timed to keep workers 
well stocked with necessary components. This new method drastically reduced 
automobile assembly times, lowered vehicle costs, and propelled the Model T to a 
dominant share of the market at the time (The Henry Ford Museum, 2003). The 
expensive, single function machinery limited flexibility and required many buffers of 
supplies, workers and storage space in order to maintain a smooth operation. 
Additionally, changing between products was an expensive and time consuming 
process due to system rigidity, and resulted in fewer options for consumers 
(Womack, 1990). 
Ford's breakthrough changed the face of the automobile industry, and 
Toyoda Kiichiro of Toyota Motors, was eager to learn from the automotive giant. In 
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1933 Kiichiro stated, "We shall learn production techniques from the American 
method of mass production. But we will not copy it as is. We shall use our own 
research and creativity to develop a production method that suits our own country's 
situation" (Ohno, 1988). The Toyota Production System was founded on the 
principle of waste elimination, utilizing autonomation and just-in-time principles. 
Under the guidance of Taiichi Ohno, this system evolved greatly from its inception 
to the present day concept of "World Class Manufacturing," with an overriding goal 
of continual and rapid improvement while maintaining flexibility (Schonberger, 
1986). These concepts have been termed "lean production" (Womack, 1990) and 
have resulted in the commitment to improve industry flexibility and competitiveness. 
1.2 Brief History of Pharmaceutical Manufacturing 
In 1938, The Food and Drug Administration (FDA) enacted the Federal 
Food, Drug, and Cosmetic Act and subsequently developed the Code of Federal 
Regulations (CFR), which contained current Good Manufacturing Practices 
(cGMP's). These practices were intended to keep the public safe and ensure quality 
products (FDA, 2006a). The pharmaceutical industry developed rapidly in response 
to the great need for penicillin and medical supplies during World War II. Following 
the war, manufacturers began researching and developing new drugs to expand the 
industry. Drug discovery evolved over the next 50 years from traditionally random 
occurrences to a highly focused methodology. Screening of target receptors and 
functional chemical structures makes it possible to identify potential successful 
therapeutic opportunities from a large pool of candidates (Ratti, 2001 ). While drug 
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discovery experienced rapid growth with relatively little regulatory oversight, the 
manufacturing areas of the industry were under the strict guidance of the FDA's 
cGMP's. These regulations resulted in a strong commitment to quality and industry 
adoption of Total Quality Management (TQM) (Ghobadian, 1995), Statistical 
Process Control (SPC), Six Sigma (Swarbick, 2006), and other quality programs. 
Rapid technological evolution of the industry resulted in cGMP's which could not 
keep pace, and ultimately had a restrictive effect on daily operations and process 
improvements for pharmaceutical manufacturers. The industry fell behind other less 
regulated manufacturing industries, where innovative practices and procedures were 
critical for global competition. 
1.3 Study Objectives 
The aim of this study is to identify critical areas for improvement in current 
pharmaceutical manufacturing practices and to explore solutions to these problems 
using principles found outside of the pharmaceutical industry. The study will be 
divided into two phases: 
Current State: 
1. The evaluation of a manufacturing facility currently producing 
pharmaceutical products under current Good Manufacturing Practices is to 
gain a "baseline" understanding of the state of the art of manufacturing. 
Using this knowledge to develop an accurate model of the system will 
identify critical and problematic areas. 
Future State: 
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2. The utilization of external industry practices, such as the Toyota Production 
System®, system designs to evaluate the introduction of continuous or semi 
continuous manufacturing. Other lean ideals and outside industry approaches 
will be used to improve the current manufacturing process and develop a new 
model. Quantitatively assess current processing standards and metrics with 
the newly designed model for pharmaceutical manufacturing based on 
manipulation of critical parameters. The theoretical improvements will 
follow the new FDA guidance documentation, as well as explore new 
boundaries. 
1.4 Study Significance 
Currently, there is little publicly available information about improving 
processes through innovational approaches. The National Institute for 
Pharmaceutical Technology and Education (NIPTE) has identified that while 
manufacturing is a significant expense to industry, there is very little industry and 
federal research funding in this area as compared to drug discovery. The lack of 
interest in funding manufacturing and processing research can be attributed to both 
the pharmaceutical industry and the FDA. The pharmaceutical industry is focused on 
bringing their product to the market place as rapidly as possible prior to the 
expiration of the patent in order to recoup the large investment made during the 
development process. The FDA is a regulatory agency concerned with product 
safety and has fostered a long tradition of discouraging risk taking involved in 
technological changes. As a result, industry has little incentive to invest dollars 
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geared at the advancement of product/process development and manufacturing 
technologies/practices. Additionally, the National Institute of Health (NIH) is 
focused on funding predominately discovery related basic research, while the 
National Science Foundation has focused on manufacturing industries that are 
critical to the economy but struggling or threatened (Couts, 2006). 
This research will serve as a model for pharmaceutical processing in order to 
encourage novel approaches to manufacturing, through specific and system wide 
solutions. Ideally this research will serve small to medium sized pharmaceutical 
manufacturers who are considering or implementing changes in their processes, 
where simply improving their current system will be inadequate to meet the future 
needs of manufacturing. Through experimental and statistical modeling, conclusions 
can be drawn about altering the traditional mentality of manufacturers to improve 
production. Additionally, because the pharmaceutical industry is so diverse, research 
must be conducted in all aspects of the field. While powder based processing 
(tablets, capsules, etc ... ) and biotechnology has received wide attention, smaller 
sectors have not been explored in depth. Contract manufacturing can be considered 
a specialty area of the pharmaceutical industry requiring flexible personnel, 
equipment and production capabilities. This research should also be considered by 
other regulated industries such as food, cosmetics, nutraceutical, etc. for viable 
methods for improvement. 
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t.5 Chapter Review 
Manufacturing has evolved over the past two hundred years and has created 
different levels for operational standards throughout industries. It is important to 
understand how the pharmaceutical industry was born and its evolution, to better 
grasp the current state of pharmaceutical manufacturers. Identifying developmental 
differences in outside industries will encourage greater fundamental understanding of 
why pharmaceutical manufacturing is unique. 
7 
Cbapter2 
2.0 Tools Utilized by Other Industries 
Chapter two will give the reader an overview of the current state of lean 
manufacturing and commonly used lean tools in order to familiarize the reader with 
methods used in outside industries. Value Stream Mapping® (VSM) is discussed as 
an important method to identify problematic areas. System configuration is 
addressed with regard to flexibility and responsiveness through parallel machining. 
2.1 Current State of Lean Manufacturing 
Toyota is the developer and leader in the use of lean manufacturing, which 
has been widely adopted with applicability to any industry. Prior to beginning 
improvement, there must be an understanding of the current system. In order to gain 
a baseline understanding of the current system, VSM has been used as a critical first 
step in the process. The process involves the investigation and recording of all 
activities involved with manufacturing of a product from raw materials to finished 
goods. By mapping the overall process, a systemic view can be created to evaluate 
total efficiency instead of individual efficiencies or areas. The map includes two 
classes of work: 1. Work that adds value to the product as defined by the customer 
(value added) and 2. Non-value added work. By addressing both types of work, a 
strategy can be devised to implement lean tools to decrease non-value added work 
and create a long term vision. The long term vision can be shown through a future 
state map which would employ the improvements and their estimated effects on the 
system (Hall, 2001). 
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Figure 1. Example of a Current State Map with additional environmental data (US 
EPA, 2006a) 
Figure 1 is an example of a current state map used by the Environmental 
Protection Agency (EPA). Definitions of the icons used in this value stream map can 
be found in appendix I. The current state map is comprised of three basic elements: 
"l. Product flow is the path(s) the product take through production, before being 
shipped to the customer. 2. Information flow is how information is shared and 
communicated during the production process. 3. Material flow deals with how 
incoming material is moved and replenished and in what quantities during 
production" (Hall, 2001 ). 
To create an accurate depiction of the three flows in the map, there must be 
accurate data from the production floor. "Gemba" is defined by Liker (2004) as the 
"actual place" and is the first step used by Toyota® when solving a problem. The 
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concept reinforces the need for first hand knowledge and challenges conventional 
management methods of system reports and computer analysis. While many tools 
can be utilized by personnel, it is important to have a firm grasp on the actual 
situation. In order to illustrate the benefits of a VSM, an example is given. The EPA 
collected the following pieces of data to create their current state map: 
• Cycle time: The average time a specific routing spends from the point of 
release at the beginning of the routing until it reaches an inventory point at 
the end of the routing (Hopp, 2001). 
• Change Over Times: The total amount of time it takes to change machinery, 
tools, personnel, etc ... from the last unit of good production at normal line 
efficiencies to the first good production unit of another product at normal line 
efficiency (Henry, 2001). 
• Total Lead Time: The EPA used throughput time, (composed of processing 
time, setup time, move time, plus waiting time) (Askin, 1993) plus delivery 
time to calculate the total time from the release of the product to the shop 
floor to the time of delivery. 
• Number of operators at each station: Additional information about manpower 
requirements versus actual staffing. 
• Inventory levels: The amount and locations of the three inventory types is 
considered. Raw materials are used to make components and sub assemblies, 
work-in-process are materials and components waiting to be completed, and 
finished goods are completed products. 
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• Uptime (Utilization): The fraction of time the system or machine is not idle 
for lack of parts, calculated by dividing the arrival rate of parts by the 
effective production rate of the machine. The effective production rate is the 
maximum average rate at which the workstation can process parts, while 
accounting for failures, setups and other pertinent factors over the planning 
period of interest (Hopp, 2001 ). 
Additionally, value stream maps can contain many more pieces of data 
dependent on the scope and depth of the project. Work schedules and time available 
to manufacture is important when calculating run ratios, which divides total available 
time to manufacture by number of good parts. Scrap rates, batch sizes, and other 
production information are useful in gaining an accurate portrait of the system. 
While much of the focus of Value Stream Mapping® is based on 
understanding the value added time and reducing the percentage of non-value added 
time, the EPA measured the baseline usage of raw materials in an effort to calculate 
the value added materials. The materials line drawn below the operational time line 
differentiates between the two classes of materials. The total amount of raw 
materials used in each process and the amount of materials that are actually 
incorporated into the product add value to the consumer. Operations chosen for 
assessment of material usage are indicated by the EHS (Environmental Health & 
Safety) oval icon based on data collection and expertise in the field. 
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Lean techniques, which will be discussed in detail later, such as 
Kaizen events, Kanban systems, Just-In-Time production and other strategies to 
eliminate waste and improve production flow, were evaluated to determine where 
decreases in the quantity of raw material usage could be achieved. The EPA then 
created an action plan for these areas of opportunity in order to decrease wasted 
materials in each operation. New values were then calculated and changes in flow 
patterns (material, informational, production) are expressed in the future state map, 
found in figure 2. 
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Figure 2. EPA Future State Value Stream Map (EPA, 2006a) 
2.2 Tools for Leaner Manufacturing 
Lean manufacturing has been considered to capitalize on the advantages of 
both mass production and artisan crafting. Cross trained workers are defined as 
"workers trained over time to perform a variety of tasks within their work area" 
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(Askin, 2002) and then often rotated throughout the positions. Utilizing cross trained 
employees with flexible autonomated processing equipment enables the production 
of a wide variety of products in high volumes. "Production is lean if it is 
accomplished with minimal waste due to unneeded operations, inefficient operations, 
or excessive buffering in operations" (Narasimhan, 2006). It is considered "lean" 
because it utilizes far fewer resources, such as worker effort, production/storage 
space, on site inventory, less equipment investments while striving to achieve defect 
free processing (Womack, 1990). 
2.2.1 Waste 
In order to improve any company's leanness, it is important to identify and 
address the seven forms of waste which were identified by Taiichi Ohno of Toyota® 
(Ohno, 1988): 
1) Defects: Parts that are manufactured but do not meet specifications 
2) Waiting: Operators/equipment that is starved for work due to a lack of 
materials, equipment, or pertinent information. 
3) Motion: Non value added movement of personnel, inventory, and/or 
equipment. 
4) Over-Processing: Any extra operations that are not required to 
manufacture a product. 
5) Over-Production: Making more product than the customer has ordered. 
6) Inventory: Having excess raw materials, work-in-process, and finished 
goods. 
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7) Inefficiency: Using excess material to process; people wasting time, 
ideas, effort, and time, and under usage of capacity (Allen & Robinson, 
2001). 
The following lean techniques were developed in the pursuit of achieving 
zero wastes. 
2.2.2 Autonomation 
Autonomation (Jidoka) in Japanese has two distinct meanings: I) A change 
from a manual process to a machine process. 2) Automatic control of defects or 
automation with a human mind (Monden, 1998). Machines normally operate at very 
high rates in manufacturing organizations; when dies or tools break there is a rapid 
proliferation of defective products if the machine is incapable of differentiating 
between acceptable and defective products. The founder of Toyota Motor 
Company®, Toyoda Sakichi, invented an auto-activated weaving machine capable of 
instantly stopping if any of the necessary threads broke. This was a significant 
finding which manifested into machinery in Toyota® plants that are equipped with 
detection sensors linked to automatic stopping devices. Additionally, workers are 
empowered and encouraged to stop production if they feel an error is occurring. 
Machinery stoppage requires immediate attention to repair and improve the system. 
If the machine can not be fixed in a set period of time, five minutes for example, then 
all members of the production team become involved with a repair solution because 
the entire production line is stopped. The cartoon below, figure 3, is a simple 
example but shows two scenarios, the top portion represents a traditional automated 
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machine which will produce whether the products are good or defective. In the 
lower portion, there is the addition of a stop button which the machine can activate 
itself in addition to a siren on top of the machine alerting the operator that there is a 
problem. Ohno said, "A problem early in the process always results in a defective 
product later in the process. This will stop the production line or change a plan 
whether you like it or not" (Ohno, 1988). 
Figure 3. Automation versus Autonomation (Hirano, 1987) 
2.2.3 Error-Proofing 
The term "Baka-Y oka" (idiot proofing) was first used by Shigeo Shingo, and 
evolved into, "Poka-Yoka" (fool-proofing) (Shingo, 1985) and is now widely 
recognized as error-proofing. This technique places various checking devices on 
equipment and tools to remove the potential for error and ultimately the creation of 
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defects. A simple example can be seen in figure 4a, where an electrical socket could 
potentially be plugged into the incorrect charge. 
Figure 4a. Electrical connection before error-proofing (QS Consult, 2006) 
This error could cause an electrical short and would result in a defective 
connection and an unusable product. When error-proofing is implemented, the part 
is redesigned to prevent the erroneous connection from being made. Figure 4b 
below depicts how a simple modification can achieve this result and remove the 
potential for error from the operator or manufacturing equipment. 
Figure 4b. Electrical connection after error-proofing (QS Consult, 2006) 
Error-proofing is used extensively throughout the Toyota Production System 
m conjunction with autonomation to minimize the production and passage of 
defective parts to the next process and to the ultimate consumer (Ohno, 1988). 
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2.2.4 Just-In-Time 
Just in time (JIT) systems require a holistic approach to ensure accurate 
production, ordering, and stock quantities to ensure that the right parts needed in an 
assembly are available at the exact time they are needed and only in the amount 
needed (Ohno, 1988). While this may seem intuitive, it can be difficult to create 
such a system for a complex product where there may be many components and 
subassemblies. Additionally, JIT systems are reliant on flexible internal and third 
party component suppliers to cooperate with variability in ordering and delivery 
agreements. This approach requires synchronization throughout the company and 
transition from traditional "push" systems to a more flexible "pull" system. Push 
systems utilize a central planning system to determine and dictate production 
schedules, based upon sales forecasts, past sales records and customer orders. The 
demand forecast is used by production control as the basis of how many components 
to purchase, how much raw material to buy, at what rate to produce and when to 
place orders (Ploss!, 1967). A pull system regulates materials and production 
through the withdrawal of only the necessary parts at the needed times from a 
previous (upstream) process which has only produced enough units to replace the 
parts that have been withdrawn. Company-wide JIT implementation results in the 
elimination of unnecessary inventory thereby removing the need for warehouse and 
storage space, while simultaneously decreasing inventory holding costs and 
improving the ratio of capital turnover (Monden, 1998). Organization wide 
implementation of JIT can be difficult, but research has shown the positive impacts 
of the system on other operational areas such as organization, human resources, 
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quality management, information systems, technology development, and 
manufacturing strategy (Matsui, 2006). This indicates a synergistic impact on a 
highly linked system and an overall contribution to competitive performance 
improvements. 
2. 2. 5 Kanban 
Kanban (sign board) is a communication tool to convey information about 
picking up or receiving the production order (Ohno, 1988). Kanbans vary in form 
(cards, bins, electronic signs, etc .... ) but they all circulate between the processes to 
control the amount of production to ensure that only what is needed is produced. 
Withdrawal Kanbans specify the type and amount of product required for the next 
process to withdraw from the previous process, and a production-ordering Kanban 
specifies the kind and quantity of product which the preceding process must produce 
(Monden, 1998). This system is vital for a pull system to maintain just-in-time 
manufacturing and prevent overproduction or underproduction of necessary 
components. Figure 6 is a simplified example of the use of Kanbans to communicate 
both withdrawal (retrieval) and production in the Toyota Production System®. 
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Figure 5. Conceptual Diagram of the Kanban System (Toyota Motor Co.®) 
While the Kanban system appears simple, it is important to realize that 
understanding and calculating the optimal number of Kanbans required is difficult. 
A system's robustness must be studied to gain an understanding of the future 
environment where unexpected events such as breakdowns occur. If the Kanban 
system is not optimized and flexible to handle variations, production will suffer and 
the benefits of the just-in-time system will not be realized (Kleijen, 2003). 
2.2.6 Kaizen 
Kaizen (good change) was defined as continuing improvement in personal 
life, home life, social life and working life. When this definition is applied to the 
workplace, the kaizen philosophy is to create an environment of ongoing 
improvement driven by company wide involvement at all levels (Imai, 1986). The 
organization must create a sense of belonging to encourage employee commitment in 
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order to facilitate the exchange of knowledge and ideas without fear of reprisal 
(Recht, 1998). Continuous improvement requires a concerted effort to identify areas 
of waste and propose solutions to those problems. Employees are encouraged to 
make suggestions on a regular basis, and these suggestions create the basis for 
continuous improvement. 
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Figure 6. Comparison of innovation and Kaizen improvement (Imai, 1986) 
Figure 6 compares innovation and Kaizen as complimentary means to 
achieve improvement, the Y-axis of graph which is not shown, over time. The graph 
uses a dashed line to represent Kaizen as continuous improvement, a vertical arrow 
depicts the results of innovation or a Kaizen blitz, and the solid line, the new 
standard, can be seen as a result of the combined effort of these actions. The term 
innovation has evolved and is now known as a Kaizen event or a Kaizen blitz. The 
focus of the event is to improve a specified process or area in a short time period, 
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through the Kaizen ideals of company wide cooperation. One expert describes the 
blitz as a week long event where a group composed of the process manager and 
personnel outside the department analyzes the current state of the process or area of 
focuses, address the problem, and implements the changes (Liker, 2004). By using 
both approaches, continuous improvement can be sustained both short and long term. 
"Ss" is a tool which can be used during a Kaizen event to reduce hidden 
wastes in the plant through a cleanup activity, and is comprised of: 
1. Sort- Organize and remove unnecessary materials. 
2. Stabilize- Improve orderliness by designating proper spaces for everything. 
3. Shine- Clean the area. 
4. Standardize- Standards are clear and understood. 
5. Sustain- Maintain the improvements and changes that have been made 
(Allen, 2001 ). 
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Figure 7. Overview of areas of improvement and benefits of using SS (Hirano, 
199S) 
Figure 7 is an overview of direct and indirect benefits of Ss in the pursuit of 
removing waste, defects and maintaining safe working conditions which is the 
ultimate goal of lean manufacturing. SS improvements will result in: 1. Product 
diversification. 2. Higher quality products. 3. Lower manufacturing costs. 4. 
Reliable product deliveries. S. Improved worker safety and 6. Higher equipment 
availability (Hirano, 199S). 
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2.3 System Configurations 
The statement "An hour lost at a bottleneck is an hour out of the entire 
system" (Goldratt, 2004) embodies the "Theory of Constraints". It is essential to 
identify a system's bottlenecks and focus on improving them in order to realize the 
full potential of the system. In order to address bottlenecks and meet customer 
demands, manufacturers must be flexible, especially when changes occur with little 
notice. 
Machine configurations ranging from serial to hybrid to parallel have been 
studied to determine their impacts on key metrics. Research investigating 
performance was defined through the following metrics: productivity, quality, 
convertibility and scalability to evaluate each configuration of equipment (Maier-
Speredelozzi, 2002). Findings indicated that a completely parallel configuration of 
machines yielded the greatest performance improvements, with hybrid systems 
yielding greater performance measurements than serial systems. While this work is 
encouraging, parallel machining is not a "cure-all" approach, as research has also 
shown that other configurations have their own advantages. Quality analysis has 
shown that serial machining had the smallest standard deviation, and different hybrid 
configurations had the smallest mean deviation and greatest convertibility (Zhong, 
2000). The complexity and needs of the system must be addressed for each 
individual facility, equipment and product. Additionally, the cost of parallel 
machining must be considered, especially for equipment with long setup and change 
over times. 
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Z.4 Chapter Review 
The basic concepts of selected lean manufacturing tools and other practices 
used in outside industries were addressed in this chapter. The overall goal of 
manufacturing lean is the elimination of waste, as this principle is applicable to every 
industry. It is important to identify where practices are applicable in the 
pharmaceutical industry. 
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Chapter 3 
3.0 Pharmaceutical Manufacturing Background 
Chapter 3 will address the current state of pharmaceutical regulations by the 
FDA through cGMP's. This chapter will discuss Process Analytical Techniques 
(PAT), a guidance approved in 2004, and regulations to improve innovation and 
competitiveness, while giving examples of this technology currently in use. 
Additionally, regulations regarding over the counter (OTC) products will be 
discussed as an appealing area for advancing manufacturing based research. Finally, 
opportunities for pharmaceutical manufacturers to take advantage of the new 
regulations will be discussed. 
3.1 Current State of Pharmaceutical Regulations for Manufacturing 
Current pharmaceutical leaders have recognized the shortcomings of 
cGMP's; examples include dubious and repetitive product testing, validation 
procedures and extensive documentation for well understood process changes. 
Inflexible regulations have hindered process improvements in the past and became 
the object of industry and FDA focus for change (Hussain, 2002). In response, the 
FDA has recently released new Guidance for Industry which addresses the use of 
PAT (FDA, 2004a) and Pharmaceutical cGMP's for the 21 51 century (FDA, 2004b). 
These documents are supported by a number of cGMP's including: Q8 Guideline on 
Pharmaceutical Development (FDA, 2006b), Q9 Guideline on Quality Risk 
Management (FDA, 2006c) and QIO Guideline on Quality Systems which is still 
25 
under development (Joneckis, 2006) to encourage innovation in the pharmaceutical 
industry. 
The FDA defines PAT as: 
A scientific, risk-based framework intended to support innovation and efficiency in 
phannaceutical development, manufacturing, and quality assurance. The framework is 
founded on process understanding to facilitate innovation and risk-based regulatory decisions 
by industry and the Agency. The framework has two components: (1) a set of scientific 
principles and tools supporting innovation and (2) a strategy for regulatory implementation 
that will accommodate innovation (FDA, 2004a). 
The definition for PAT presented does not define the overall strategy of the 
initiative, but serves as an introduction to the regulatory practice. A practical 
definition of PAT is given as "systems for continuous analysis and control of 
manufacturing processes based on real-time measurements, or rapid measurements 
during processing, of quality and performance attributes of raw and in-process 
materials and processes to assure acceptable end product quality at the completion of 
the process" (Hussain, 2002). These revised guidance documents have created a new 
era for the pharmaceutical industry. The documents shift away from conventional 
thinking, where process changes are discouraged due to the substantial financial and 
scientific resources required to fulfill FDA documentation requirements. The new 
focus is to understand the product, the manufacturing process, and operations. This 
approach has been described as the "design space'', defined by the FDA as: 
... the multidimensional combination and interaction of input variables and process 
parameters that have been demonstrated to provide assurance of quality . Working within the 
design space is not considered as a change. Movement out of the design space is considered 
to be a change and would normally initiate a regulatory postapproval change process. 
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Design space is proposed by the applicant and is subject to regulatory assessment and 
approval (FDA, 2006a). 
Within the design space, the control space has been described as a: "Multi-
dimensional space that encompasses process operating parameters and component 
quality measurements that assure process or product quality. It is a subset of the 
design space" (Desai, 2006). Exploration and understanding of these areas will lead 
to the identification of critical parameters, as well as metrics and methods to capture 
their impact on the process, enabling quality management through a risk based 
approach. A new control strategy aims to minimize risks associated with failures 
when critical and non-critical process parameters fall outside the control space but 
remain within the design space. 
The FDA has recognized, similarly to outside industries, that quality must be 
built into the design of the product, and that it cannot be achieved through testing or 
inspection alone. Throughout the development and product life cycle, changes in 
formulation and manufacturing practices offer opportunities to gain greater 
knowledge of product characteristics and performance under various conditions. 
Inclusion and analysis of all relevant experimental and experiential information can 
be used to create, support, and expand the control and design spaces. While absolute 
operational and process understanding is impossible, it is important to recognize 
what is known and operate within those parameters. Figure 8 depicts a conceptual 
representation of the importance of experimental data to provide the framework for 
creating and supporting the control and design spaces as defined by the manufacturer 
and approved by the FDA. 
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The FDA has given the pharmaceutical industry an opportunity to enter the 
21st century of manufacturing by expanding the control space of their operations 
while still staying within safe operating conditions in the design space. PAT has 
excited many in the pharmaceutical industry, who see the potential to continuously 
improve processes as they occur in other manufacturing industries. 
This drastic change in the regulatory mindset has raised many questions 
regarding feasibility and practicality. PAT has become an industry "buzzword" with 
much of the knowledge only attainable through consultants, and/or is guarded 
closely within the industry. Current seminars and workshops address very specific 
ideas of using novel techniques for limited areas, such as specific assays used during 
processing to verify quality (Tyler, 2006). Many consultants propose vague 
"buzzword" laden approaches to improvements without scientific background and 
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appear to be more oriented to selling their services. Adoption of PAT has been slow 
due to a lack of technical knowledge and trepidation over regulations, as PAT is 
currently only a guidance document and not a requirement. 
PAT is still in its early stages of use, and there is wide spread skepticism and 
uncertainty of how the FDA will regulate this new area. While the long term 
benefits of manufacturing improvements are clear, it is difficult to make the 
argument for a sizable investment in innovation on a product currently being 
developed for fear of clinical failure and the uncertainties of FDA product approvals. 
Further, if a product will be approved, companies want to avoid delaying or 
jeopardizing the approval process due to changes in manufacturing approaches. 
Additionally, there are concerns over technological limitations, which prevent online 
process monitoring and understanding for complex products such as protein drugs 
(Glaser, 2006). Others have addressed some of these concerns in outside industries 
and it is important to learn from their successes and failures. 
3.2 Examples of Current PAT Use 
Near infrared (NIR) spectrometry has been studied extensively for the use of 
online monitoring of pharmaceutical products. This non-invasive and non-
destructive technique has been studied for a number of different potential uses during 
manufacturing. This method can identify and differentiate between differently 
formulated products even if they appear identical, across a wide variety of dosage 
forms (tablets, solutions, capsules, etc) (Medendorp, 2006). NIR has been studied 
throughout the manufacturing process, from raw material qualification and 
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quantification, in line monitoring processes and final packaging identification 
systems. Some monitoring applications include moisture content, active 
pharmaceutical ingredient (API) concentrations, blending homogeneity, coating 
thickness and tablet hardness (Swarbick, 2006). 
Raman spectroscopy utilizes an energy source, such as a laser or ultra violet 
(UV) light, to excite molecules from their original states into an excited state, and 
measures the vibrational level required for the shift (Raman, 1928). This tool has 
been used in the identification, monitoring of homogeneity, and quantification of 
different drug products. Polymorphs, defined as a drug substance existing as two or 
more crystal chemical structures which may have different chemical and physical 
properties than the original structure (FDA, 2002), have been identified as an 
opportunity for processing improvements. Continuous monitoring of polymorphic 
transformation secondary to high sheer granulation in formulations for encapsulation 
and the solubilization of API in inactive ingredients (excipients) has been studied 
(Jayawickrama, 2006). Raman probes have been placed in different machinery 
during production to determine that this technique was viable for monitoring process 
deviations, which negatively affect the product. Monitoring and adjusting 
processing to prevent undesirable polymorph formations through online Raman 
monitoring to retain formulation homogeneity is an important tool for manufacturing 
acceptable products (LaPlant, 2005). Currently, Raman and Infrared techniques are 
limited to process monitoring but future developments should aim to incorporate 
autonomation principles such as automatic processing adjustments when deviations 
occur and automatic shut downs if adjustments do not solve the problem. 
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There are a number of other methods of utilizing analytical and process 
instrumentation to identify acceptable processing and product specifications. A few 
examples are included here: Mass spectroscopy has been proposed to monitor 
moisture content of drug products during lyophilization to ensure acceptable 
processing conditions to yield less than 1 % water content (Wiggenhom, 2005). Cell 
density probes have been utilized to monitor the fermentation process of protein 
drugs, to reduce potential quality issues, process variability and meet the desired 
target density with fewer deviations (Low, 2006). 
Pharmaceutical manufacturing requires that strict processing and formulation 
specifications must be met prior to the release of the product. Currently, 
manufacturers must "test in" quality by sampling a number of randomly selected 
finished products prior to their release, known as end product testing. By monitoring 
important metrics during production with a demonstrated correlation with end 
product quality, one could conceivably avoid end product testing and utilize in-
process (parametric) release testing. In 1987, The FDA approved parametric release 
only for terminally heat sterilized drug products. Parametric release is defined as "a 
sterility release procedure based upon effective control, monitoring, and 
documentation of a validated sterilization process cycle in lieu of release based upon 
end-product sterility testing. All parameters within the procedure must be met before 
the lot is released (FDA, 1987)." This regulation only applies to certain large 
volume parenteral (L VP) products and requires a supplemental new drug application 
for approval. Currently several manufacturers have gained approval for parametric 
release using moist heat sterilization (autoclave) methods, but it has not been adopted 
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widely due to the extensive documentation and validation procedures required 
(Stevens-Riley, 2005). Chemical, ionic, and thermal methods of terminal 
sterilization for many drug products to avoid end product sterility testing and allow 
parametric release have been discussed by members of the United States 
Pharmacopeia (USP) for FDA approval {Tirumalai, 2005). 
3.3 Over-The-Counter Product Regulations 
There are more than 100,000 over-the-counter (OTC) products and 800 active 
ingredients, encompassing over 100 therapeutic classes currently for sale in the US 
(FDA, 2000). There are two methods to get an OTC product on the market to sell to 
the general public without a prescription. Similar to new prescription drugs, a New 
Drug Application (NDA) for a specific product must be approved prior to marketing 
which may require clinical studies, mandated FDA review timelines and post-
approval maintenance (Christ!, 2006). An alternative method is to be in compliance 
with an FDA approved drug monograph. Monographs specify active ingredients 
which must comply with standards that have been found "generally recognized as 
safe and effective" (GRASE), and must comply with the monograph with regard to 
the formulation, labeling, and testing requirements (FDA, 2006d). The United States 
Pharmacopeial Convention is an independent volunteer organization recognized by 
the FDA to set monograph standards for active and inactive pharmaceutical 
ingredients, dosage forms, and medical devices (USP, 2007). Monograph products 
do not require pre-approval or clinical trials; they have common labeling for all 
similar drugs and are publicly available without exclusive marketing rights. The 
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similarities between NDA and monograph products include: safety and efficacy 
standards, manufacturing and GMP inspections, labeling requirements and 
advertising regulations (Hilfiker, 2006). 
OTC monograph products represent an opportunity to investigate new 
manufacturing techniques. Formulation, dosage form, concentration requirements 
and labeling are the key monograph factors (Hilfiker, 2004), while manufacturing 
processes are generally left to the manufacturers. This flexibility allows 
manufacturers to individualize specific processes to create their own version of the 
product. During the approval process for a prescription drug, clinical or 
bioequivalence studies are required and the manufacturing processes used during this 
period must remain the same after approval. If there is a significant change to the 
production process, it must be validated and documented in a supplemental 
document. The financial and time constraints cause pressure to gain an expedient 
approval, and can later result in non optimal processes which are not changed for 
fear of negative FDA action. As a manufacturing model, it would be more feasible 
to use an OTC monograph product because it has been characterized and studied. 
While monographed products still require validation for changes during 
manufacturing, there is a greater flexibility and information available during the 
initial production process planning. 
3.4 Opportunities for Pharmaceutical Manufacturing 
There is considerable opportunity to investigate the implementation of 
current practices and knowledge found outside the pharmaceutical industry for 
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incorporation into novel processes in line with the FDA's cGMP's and PAT 
regulations. The concept of the incorporation of external industries has been 
proposed (Crosby, 2006), but research focused on these principles and their effects 
on manufacturing operations and pharmaceutical product development has not been 
explored. It is important to approach improvements to manufacturing while still 
complying with cGMP and FDA regulations. Each product and manufacturer should 
asses whether changes in their regulatory requirements are necessary if changes are 
made. 
3. 4.1 Batch vs. Continuous Processing 
One of the most apparent areas that could be improved in the pharmaceutical 
industry is a change from batch manufacturing to a continuous manufacturing 
approach. Currently the metal industry has utilized continuous manufacturing for 
metal matrix composite wires, among other products. Originally the wire was 
manufactured by batching, but long processing times and extended heat exposure 
was detrimental to the final product. The process was redesigned addressing the 
critical parameters required for a quality product, and thorough experimentation was 
performed in order to identify the optimal operating parameters of the new process. 
The new process yielded lower throughput times and lower exposure times which 
had resulted in heat damage to the metal and an unacceptable product (Blucher, 
2001). 
Some areas of pharmaceutical production have considered continuous 
production methods. Tablet, transdermal patch and biotechnology product 
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manufacturing have been studied to determine the potential advantages of continuous 
manufacturing practices. Granulation is a method to increase powder flow and 
compressibility (Ansel, 1999), and is often a bottleneck in tablet manufacturing. 
Some continuous production methods which have been considered to overcome this 
problem include: fluid bed agglomeration, spray-drying, extrusion, instant 
agglomeration, roller compaction and semi-continuous granulation. Continuous 
transdermal patch manufacturing using hot melt extrusion principles has been 
studied (Wolff, 2000). Spray drying techniques, used extensively in the dairy 
industry, have been used in the biopharmaceutical industry but have been 
increasingly displaced by lyophilization, a batch process. Ease of automation, lower 
material handling, in-process controls, flexible manufacturing and avoidance of 
scale-up are some advantages of a continuous system (Vervaet, 2005). It is 
important to consider that continuous practices are not a "one size fits all" 
application, and individual products must be critically evaluated. This methodology 
can be applied early on in the development phase, when considering formulations, 
but it is critical to evaluate the formula's performance during the manufacturing 
process, in vitro and in vivo. If production .volumes are kept constant, continuous 
manufacturing would require significantly smaller space and equipment, potentially 
yielding a several fold cost reduction (Cini, 2006). 
Currently there are technical and regulatory barriers which must be addressed 
prior to the commercial institution of continuous manufacturing. Few manufacturing 
systems can be easily adapted to a continuous process without significant capital 
investment. Publications in this area are sparse, and narrowly focused on a single 
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product, requiring expansive experimentation to gain the information required to 
change. Additionally, some products are made in small quantities and production 
goals can be met in a single batch. The FDA has given manufacturers theoretical 
guidance, and the industry is unsure of the regulatory agent's interpretations of the 
new documents. Manufacturers should not overlook previously discussed lean 
techniques which could be evaluated and applied to the pharmaceutical industry now 
for results in the near future. 
3. 4. 2 Lean Techniques 
Currently, setup times are very long for equipment and result in large batch 
processing to preserve their economy of scale. The Toyota Single Minute Exchange 
of Die (SMED) concept is focused on reducing the setup time for equipment which 
had traditionally taken several hours to less than ten minutes. This significant 
accomplishment occurred through continuous improvement by employees at 
Toyota®. Continuous improvements in setups in pharmaceutical companies could be 
achieved utilizing shadow boarding, a visual control technique, which creates an 
outline for mechanics tools and parts required for assembly of equipment, to ensure 
that parts are not missing or incorrect. Currently, standard operating procedures 
(SOP's) are required by the FDA, but may be unclear when compared to visual 
controls used in many automotive manufacturing facilities. Standardized work and 
error proofing techniques are aimed to aide manufacturers through simplification and 
visualization of the process. While many SOP's may include sample graphs or 
tables with information, they often do not utilize pictures or simple drawings to 
36 
instruct the operator. SOP's can be technical and difficult to understand resulting in 
operator deviations. Simplification of the process, such as color coded setup 
components, or creating one way assemblies of parts can simplify the setup and 
change over tasks, while reducing the chance of an erroneous setup resulting in 
damage to the machine or the product. 
A pull system could be used to mcrease product flow through the 
manufacturing facility and movement towards one piece flow. Predominantly the 
formulation aspect of pharmaceutical products requires a batch process to generate 
the bulk drug. The following stages could utilize a semi continuous approach to 
decrease batch sizes similar to Toyota® production method. Batch splitting or mini 
batching could be explored to increase flow and flexibility in the remaining 
operations. Kanban cards could be used to facilitate the pull system, especially since 
the master batch record currently travels with the product throughout processing and 
acts as a production Kanban. Retrieval Kanbans could be used to help create greater 
visualization of where equipment and material should be placed to support the flow 
of production. 
3.4.3 Designfor Manufacturing 
Design for Manufacturing (DfM) principles have been studied extensively for 
products such as wiring harnesses, electronics, machining of metal components, 
powder metal processing, plastic injection molding, sheet metalworking, casting, and 
final assembly (Bralla, 1986; Boothroyd, 2002; Otto, 2001 ). There are opportunities 
to develop similar principles for the development of drugs and medical device 
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products. Traditional development methodologies are concerned only with creating 
a safe and efficacious product. The product is then given to the manufacturing 
department and is expected to be produced rapidly, despite the fact that 
manufacturability was not considered at all during the design process. In reality, the 
transition from development to manufacturing is a difficult and complex process. 
Using principles from DfM to guide experimentation during formulation, 
identification of factors that are critical to the manufacturability of the product will 
support expansion of the design space to allow more flexible manufacturing. 
Examples of experimental focal points include raw material properties, variation of 
formulation characteristics and delivery device components. 
3. 4. 4 Simulation 
Simulation has been used throughout many industries to gain insight into 
current conditions and hypothetical future states. Mathematical models and 
simulations have been used in operations research for many years to solve 
operational, warehousing, transportation, distribution and logistical problems 
(Chung, 2004). Simulation has been expanded to address a wide array of 
problematic areas for industries outside of manufacturing. Lean manufacturing 
principles have been studied to determine suitability for specific industries in order 
to evaluate conceptual improvements that could be made through its implementation 
(Abdulmalek and Rajgopal, 2007). By creating a value stream map as the foundation 
of their simulation model, Abdulmalek and Rajgopal evaluated implementing lean 
techniques to a steel manufacturer and determined which improvements were 
38 
feasible. The simulation allowed the researchers to monitor WIP and production 
lead time as their primary metrics, while creating a visual product for management to 
encourage changes where needed. 
3.4.5 Other Manufacturing Tools 
Parallel and flexible machining could also be used in many of the processes 
after the bulk drug has been formulated. Filling bulk product into its container, 
cartoning of filled drug product and boxing of finished goods are all strong 
candidates for parallel machining. Utilizing flexible routing and reconfigurable 
machines can reduce throughput time and minimize the effects of downtimes. Also, 
resources required for production may be shared, and have a synergistic effect on 
production rate and setup times. 
Online and in line sensing methodology is continuously evolving and has the 
potential to change the way processes are monitored. Unfortunately the current 
limitations are sensitivity issues and equipment can not accurately analyze all aspects 
of the manufacturing processes. As the sensing and analytical technology improves, 
manufacturers can rely greater on processing parameters and less on end product 
tests. 
3.5 Chapter Review 
The current state of the regulatory influences guiding the pharmaceutical 
industry was addressed in this chapter. New guidance documentation and the 
opportunities which have arisen for the industry were addressed. The opportunities 
addressed may not apply to all pharmaceutical manufacturers, and it should be noted 
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that there is varying commitment to lean manufacturing throughout the industry. 
particularly small and medium companies with more limited resources may need to 
explore these techniques. 
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Chapter 4 
4.0 Methodology and Procedures 
Chapter four will describe the methods and procedures used to gam an 
understanding of a product throughout the current system of the company used in 
this study. Collected empirical data are defined as model inputs to accurately portray 
the product in the system. A simulation model will be employed to allow 
visualization of the process and for identification of problematic areas. A theoretical 
future state will be created in ProModel® software and compared against the original 
current state to identify which changes to the system yield a significant impact. 
4.1 Phase I - Current State of Pharmaceutical Manufacturing 
Phase I will evaluate a manufacturing facility that produces pharmaceutical 
products under current Good Manufacturing Practices to gain a "baseline" 
understanding of current manufacturing systems. This phase will develop a model 
of the system to identify critical and problematic areas, to identify potential 
opportunities for processing and formulation improvements. 
4.1. 1 Evaluation of the Current System 
The current manufacturing system will be evaluated by "walking the line" 
and "gemba" (go and see) lean manufacturing techniques (Meier, 2001) to create an 
accurate current Value Stream Map®. VSM inputs will include the collection of 
direct measurements, historical data and empirical information. Manufacturing data 
will be collected through direct and indirect methods, including time and motion 
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studies and the measurement of factors such as Work In Process (WIP) throughout 
the system, productivity, rework/scrap rates and other critical manufacturing 
indicators (Hopp, 2001 ). An AutoCAD® drawing of the layout will be used to 
measure distances traveled by personnel and materials. Detailed employee shifts 
with breaks will be collected to measure total work hours in a day. Delivery times 
and quantities will be documented to monitor the flow of materials into and out of 
the production facility. 
Direct methods: 
• Measuring throughput time, cycle time and change over/setup times. 
• Counting materials, components, Work in Process (WIP) and finished 
goods throughout the system. 
• Machine utilization/uptime and operators required. 
• Counting defects, rework and scrap rates. 
Indirect Methods: 
• Quality Control Master Batch Records. 
• Other documentation recorded during the manufacturing process. 
4.1.2 Simulation Modeling 
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Figure 9. Simulation Overview (Sanchez, 2006) 
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Figure 9 gives an overview of the steps required to create an accurate 
simulation and how experimentation can be performed to gain insight into "real 
world" problems in the current system. ProModel® software is a tool for simulating 
and analyzing diverse production systems including assembly lines, transfer lines, 
flexible manufacturing systems, job shops and Just-In Time systems. Resource 
utilization, production capacity, efficiency, inventory levels, etc. are some of the 
elements which can be modeled (PROMODEL, 2003). This software will allow 
experimentation with numerous variables, such as equipment, personnel, and layout 
with only conceptual alterations to the manufacturing facility. Data collected will be 
analyzed to identify trends, which enhance production metrics, (throughput, Work in 
Process, cycle time, etc.) (Hopp, 2001) and those that are detrimental to efficient 
production. Simulation will allow visualization and will incorporate detailed 
information about the system while closely conforming to the individual aspects, 
(Askin, 1993) facilitating experimentation with theoretical scenarios to identify 
problematic areas and potential failures. Phase one will result in the 
characterization and creation of a simulation model of the existing manufacturing 
system to identify the current manufacturing state. 
4.1.3 Statistical Methods 
In order to identify the most critical parameters after phase I, statistical 
analysis will be used to determine factors of interest which will be tested during 
phase II. A quality by design (QbD) method using a Box-Behnken design has been 
recently employed by Zidan et al. (2006), and will serve as a model. Critical factors 
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will be identified in phase I and ranked according to perceived impact and an 
appropriate statistical design will be chosen based on the number and type of factors. 
The top factors, approximately three or four, will then become the statistical focus of 
the phase II simulation, with each of the factors containing appropriate levels for 
thorough study. Examples of potential critical areas include identification of 
bottleneck workstations, problem areas (defect/scrap rates) and unreliable 
operations/operators. The significance of interactions between independent and 
dependent factors will be evaluated through analysis of variance (ANOV A), with 
graphs to enhancing visualization where appropriate (NIST, 2006). Minitab® 
Statistical software, Minitab Inc. Pennsylvania, USA (or equivalent) will be used for 
all statistical analysis and generation of appropriate tables, graphs and charts. 
4.2 Phase II - Future State of Pharmaceutical Manufacturing 
Phase II will utilize the information gained in phase I to compare current drug 
processing with a model of a theoretically and experimentally based "improved" 
system. Improved systems will address the critical processing parameters identified 
in phase one, and employ concepts adapted from alternative industries to gauge 
feasibility and potential outcomes. 
4.2.J Development of the Future State Model 
To address the identified critical parameters, manufacturing tools from across 
all industries will be utilized including The Toyota Production System®, flexible 
manufacturing system designs, continuous processing methods, in-line product 
testing and additional manufacturing tools. New processing and techniques for 
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manufacturing will be analyzed to determine feasibility, using simulation to 
understand the impacts. Experimentation comparing alternative layouts and 
theoretical flexible systems to enhance production while potentially minimizing 
space and expenses will be performed using simulation (Askin, 1993). 
A design of experiment using a factorial design was chosen in order to 
identify which interactions and factors achieve statistical significance. Table 1 
describes the 23 factorial design employed to compare the different simulation 
models. There are three factors where the current state for each factor is denoted as 
zero, and the future state is denoted as 1. Therefore, run 1 depicts the current state of 
the system and run 8 is the most radically changed future state. In order to evaluate 
which areas of the future state are significant, six other intermediate simulations will 
be run, where some factors will be modified while others remain the same. 
Table 1. Overview of Experimental Design 
Factors 
Scenarios A 8 c 
1 0 0 0 
2 0 0 1 
3 0 1 0 
4 0 1 1 
5 1 0 0 
6 1 0 1 
7 1 1 0 
8 1 1 1 
4.3 Chapter Review 
This chapter describes the methodology that will be used to evaluate a 
pharmaceutical manufacturer and a specific product. Using simulation and lean 
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tools, identification of problem areas and solutions will be evaluated. Additionally, 
by using a statistical design, interactions between factors can be evaluated for 
significance. 
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Chapter 5 
5.0 Case Study 
Chapter five will describe a pharmaceutical company which was selected as a 
case study for manufacturing improvements. The current manufacturing processes 
of a product chosen as the focal point of the study will be described and evaluated. 
A value stream map will guide the reader through the process and indicate where 
value and non value added time is expended on the product. The data collected and 
used to prepare the value stream map and the ProModel® simulation model will be 
described in this chapter. 
5.1 Background of the Pharmaceutical Company Selected for Study 
The pharmaceutical company chosen for this study will be referred to as 
XYZ Pharma in order to maintain their anonymity. While the company produces a 
few proprietary and prescription products, it primarily serves as an OTC contract 
manufacturer, producing over 100 human and veterinary products. Management 
currently describes that they are slightly behind schedule to meet customer deadlines, 
but feel that they are one of the more reliable and capable contract manufacturers in 
their market area. 
5.1.J Facility 
The facility has the capacity to produce oral products such as liquids and 
suspensions, and topical products including gels, creams, liquids, adhesives and 
more. This study will focus on issues affecting topical gels and their manufacturing. 
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The company is comprised of a 25,000 sq./ft. production facility and a 75,000 sq./ft. 
detached warehouse building, approximately 1/10th of a mile away. The production 
facility layout can be seen in Appendix II, while the warehouse building, (not shown) 
is not considered the primary area of study. Unlike many other manufacturers with 
dedicated manufacturing equipment and personnel, XYZ Pharma is a self described 
pharmaceutical "job-shop". At any given point they are manufacturing between five 
and seven different products simultaneously throughout the production facility in 
various formulation, filling and packaging areas. The company does not have a 
yearly shut down period and strives to meet customer needs in a flexible and timely 
manner. 
Due to the high volume of products being manufactured and the need to meet 
deadlines, the overall maintenance of the facility is lacking. While there is an 
employee dedicated to cleaning and waste removal, large amount of cardboard boxes 
can be found throughout the facility. Additionally, empty chemical containers, 
usually 55 gallon drums, can be found in large numbers, 60-90 at any given time. 
These barrels are removed by a recycling company which compensates XYZ Pharma 
at an approximate rate of $2 per barrel. Currently, the recycling company will 
remove all unwanted drums at the request of XYZ Pharma, which occurs 
occasionally every 10-14 days. Materials waiting for recycling are stored in the 
loading dock area, and often monopolize 75% of that area, creating obstructions 
during loading and unloading of trucks. Material handlers must frequently move raw 
materials and finished goods multiple times to access blocked pallets. 
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5. J. 2 Personnel 
There are approximately 55 employees. Many employees are temporary, but 
permanent employees have between 5 and 15 years of experience at their position. 
There are three overlapping shifts: shift 1 starts at 5:00am and ends at 2:00pm, shift 
2 begins at 7:30am and ends at 4:00pm, and shift 3 begins at 2:00pm and ends at 
10:30pm. Each shift is entitled to two 15 minute breaks and a 30 minute lunch 
period. There are currently two mechanics who service all of the filling and 
packaging lines in the facility, with a third mechanic in training. Two manufacturing 
specialists formulate all topical products. There is currently one "dishwasher" 
responsible for sanitizing parts and components for equipment, but he feels there is 
need for another full time washer. Two material handlers move most of the 
components and trash in the facility, but often assist in other areas when needed. 
There are between 20 and 30 operators during the shifts to run the filling and 
packaging machines. Only a select group of operators have been trained on the 
newest filling machine, and their operating times are limited to the second shift 
(7:30am - 4:00 pm). During slow periods, operators build inventories of boxes or 
they are sent home. There is currently a surplus of operators, who are occasionally 
given time off due to lack of work. 
5.1.3 Quality Control 
The quality control (QC) department functions to ensure that all shipments 
received and products exiting the plant meet quality specifications. The QC 
department consists of a laboratory based group with five analysts. All incoming raw 
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chemical ingredients and packaging materials must be placed into a "quarantine" 
area. This designation identifies that the materials have not been tested to ensure that 
they meet the required specifications. A QC analyst must sample the quarantined 
material and upon successful testing, the material is released to the general 
production warehouse area or production facility. Raw materials will generally 
spend between one and two weeks under quarantine before they are released for use. 
This group is also responsible for all analytical testing of the bulk formulated drug 
substance, the final product filled into packaging and stability studies required to 
determine expiry periods. 
The other function of the QC department is the monitoring of all 
manufacturing operations and documentation. This section of the QC department is 
comprised of 6 inspectors and a supervisor. There are 12 total QC employees 
responsible for ensuring quality and proper documentation at XYZ Pharma. 
Inspectors rotate around the facility to monitor a number of processes at once and 
must record their findings in the master batch record. The master batch record 
captures manufacturing and formulation data and is vital for the manufacturer to 
prove to the FDA that all SOP's, and cGMP's were followed. All equipment must 
be inspected by QC prior to machine setups to ensure that proper cleaning has 
occurred and there are no residual materials on the parts. To ensure proper 
formulation, QC is required to initial the batch record along with the manufacturing 
specialist after every step in the process. Tube filling is monitored by checking the 
weight of 5 tubes every half hour to ensure accurate fill weights. Filled tubes placed 
into cartons must be inspected every half hour to ensure the machine is producing a 
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legible lot number and expiration date on the cartons. This monitoring is in addition 
to visual and weight measurements taken by the operators and supervisors to make 
adjustments to the machines on a regular basis, approximately every 15 minutes. 
Finally, it is the responsibility of a separate dedicated QC inspector to reconcile all of 
the batches manufactured. Finished goods are considered to be quarantined again 
until the product has been fully tested and the shipping release has been completed, 
which may take up to a day or two. All packaging components, raw materials, 
defects and finished goods must be counted. All of the inventory must be accounted 
for and finished goods production must be within 10% of the desired goal. The QC 
supervisor then must compile the master batch record with the reconciliation 
documents and acceptable test results from the QC laboratory group's quality tests. 
When all of these documents are compiled, the shipping release sheet is created and 
signed by the supervisor in compliance with FDA regulations. The batch is then 
released, removed from the quarantine area and ready to be shipped out to the 
customer. 
5.1.4 Deliveries 
One driver is responsible for operating and filling XYZ Pharma's truck, 
which travels between the main warehouse building and the production warehouse 
area in the production facility with raw materials, finished goods and recyclables. If 
material handlers are available, they will assist the driver in loading or unloading the 
truck. The truck is on a continuous delivery schedule beginning at 7:30am and 
ending at 4:00pm. Occasionally, the truck will make deliveries or pickup materials 
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from an outside company and material will buildup in both buildings. The truck 
completes one trip where it is loaded and unloaded between the two buildings in one 
and half to two hours. These milk runs create a steady flow of materials entering and 
exiting the system. Currently, the truck is not always filled before it departs from the 
production facility loading dock. Poorly marked components for return or the 
unknown status of a finished good prevents the driver from independently making 
return decisions. If cardboard is to be recycled, it will be taken to the warehouse if 
the pallet has been wrapped by the pallet wrapper and placed in the loading dock or 
storage facility, but the driver will not actively search for additional return materials. 
Instead, a warehouse supervisor must instruct the driver what to remove. 
Additionally, the last truck load at 4:00pm leaving the production facility is empty 
and stored at the warehouse building's loading area. 
The external shipping truck, operated by a freight company, arrives at the 
warehouse production area daily between 1 :OOpm and 3:30pm, and serves to ship 
finished goods inventory or deliver small packages of raw materials. Small packages 
of raw materials are generally less than 5Kg and are stored in a designated area of 
the production building for easy access by manufacturing specialists during 
formulation. Large quantities of incoming materials from the external shipper arrive 
at the warehouse building daily. Outgoing shipments of large finished good orders 
are removed to the warehouse building as well, where there is ample storage room to 
organize and store the order. Lead times for raw materials vary, with readily 
available chemicals arriving daily with a 1-2 week lead time. This is in stark contrast 
to custom printed plastic tubes and packaging materials which arrive once every 4 
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months due to their long lead times of 8-12 weeks. Long lead times for materials, 
coupled with time spent in quarantine results in XYZ Pharma holding a large amount 
of raw materials inventory in order to meet variable customer demand. 
5.2 Current State for Manufacturing of Product X 
This study will evaluate the manufacturing of a poloxamer based topical gel, 
referred to as product X, sold in a one ounce tube with an average yearly production 
of 120,000 tubes per year, produced in 30,000 tube batch sizes as requested by the 
customer. This product is similar in formulation and manufacturing processes too 
many other products manufactured at XYZ Pharma and is representative of the 
system. 
Production schedules are generally made weekly in response to customer 
purchase orders, but last minute changes occur if customer deadlines are missed or 
the order is changed. In response to the schedule, a material requisition and a 
packaging requisition are sent to the production warehouse area where raw chemical 
ingredients and packaging components, such as tubes and cardboard boxes, are 
primarily stored. The materials requisition indicates the type and quantity of 
chemicals that are required for the formulation of the product. The packaging 
requisition indicates the type and quantity of components required to package the 
formulated material. All ingredients and components are held in quarantine until 
verified by quality control (QC) through an identification assay to ensure identity 
and potency, or compliance with specification limits for components. The individual 
components are weighed and product is then formulated by a manufacturing 
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specialist and filled into a large storage vessel. Unused raw materials that are no 
longer needed for formulation are returned to the production warehouse area, where 
they are returned to the main warehouse building. Theoretically, a sample of the 
bulk formulated product from the vessel should be assayed before filling into tubes. 
However, the bulk is often assayed by QC at a later time, while the product is filled 
into tubes and concurrently undergoing end product QC testing of finished goods. 
The vessel may be taken to the filling machines for immediate tube filling but is 
more commonly stored until a machine is available. The vat is then moved to the 
filling machine, where tubes are filled and crimp sealed. The filled tubes are stored 
near the cartoning machine or intermediate manufacturing holding area until the 
batch is finished or nearing completion. The manufacturing process has undergone a 
validation procedure, which requires only one tube selected at random to be tested by 
QC for end product release testing. The tubes are then loaded into cardboard cartons 
and filled into boxes with preprinted company labels. Filled boxes are loaded onto 
pallets and wrapped in protective plastic, before being moved to a quarantine area. 
After all QC assays, reconciliation, and necessary documentation are complete, a 
shipping release form is completed and the product is ready to be shipped to the 
customer. A schematic overview of the process and the material flow through the 
buildings in which they take place can be seen in figure 10. 
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Figure 10. Material Flow Chart 
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5.2.1 Formulation of Product X 
Prior to formulation, all equipment, parts, and the manufacturing area must 
be inspected and documented for cleanliness by the QC department. ., Visual and 
smell tests have been validated with chemical analysis support to identify residual 
materials from previous batches. Upon QC's approval, equipment setup begins and 
the manufacturing specialist assembles the machinery for use depending on the 
product to be produced. The manufacturing specialist is responsible for all 
fonnulation equipment and other materials such as pumps, tubes, etc. There is one 
equipment washer who works during the second shift and is responsible for cleaning 
the machine parts. When he is not working, or if the cleaner is overwhelmed, the 
manufacturing specialist must clean the parts needed for setup. This may result in 
used kettles left over night, or weekends until the manufacturer is available to clean 
the area. 
Product X is comprised of six ingredients which are brought from the 
warehouse, while deionized water is hard piped and validated for purity to meet 
necessary standards into the manufacturing area. Chemicals are stored outside of the 
manufacturing area, if space is available, or held in the production warehouse area. 
Each ingredient must be weighed, checked, and then documented to be accurate by 
both the QC inspector and the manufacturing specialist. The ingredients are then 
added in a four phase approach to ensure a pharmaceutically elegant and accurate 
product. Empty drums are taken to the cleaning area by the manufacturing specialist 
during production to keep the manufacturing area clear. Excess raw chemical 
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ingredients are placed outside of the manufacturing area for return to the warehouse, 
or future use. 
Product X is formulated in a 1000 L capacity Lee Kettle® equipped with a 
sweep mixer and a built in Toledo® scale. A smaller 300 L Hubert® mixing vat is 
used for high shear mixing and solubilization of material prior to transfer with an air 
pump into the Lee Kettle®. The product undergoes a 23 step formulation process, 
which is described specifically in the Master Batch Record and that can be 
categorized as weighing and addition of ingredients, mixing, heating, milling, 
material transfers and de-aeration (settling). During the production period, the QC 
inspector periodically checks on the manufacturing specialist dependent on which 
step he is performing to verify his work and sign the master batch record. The 
product is completed when it has been entirely transferred into a stainless steel 
storage vat through a milling process. Table 2 gives the data collected through time 
studies. The value added time has been identified and serves as the basis for the 
calculations of the formulation kettle's uptime. 
Table 2. Data of Formulation Time for Batch #2 
Value Non Value 
Added Added 
Formulation Action j_Minl J_Minj 
Chan_g_e Over 662 
10:21 Start 24 
10:45 StoR Went to _g_et Scale 3 
10:48 Start 21 
Went to Dispensory for 
11:09 StoR Chemical 6 
11 :15 Start 56 
12:19 StoR Lunch 41 
1:00 Start 25 
1:25 StoR Waitin_g_ for QC 5 
1:30 Start 25 
1:55 St OR Went to _g_et ScooRer 4 
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1:59 Start 198 
5:17 Sto_.E_ 120 
Millin_g_ Transfer 469 721 
Total 
5.2.2 Filling of Product X 
A mechanic is responsible for the setup of the filling equipment and must 
have a QC inspector check all of the parts for cleanliness prior to setup of the 
machine. The mechanic performs the machine setup, and must prime the machine 
with product to make adjustments and ensure accurate filling within specifications. 
Product X is filled into the hopper from the storage vessel using a transfer pump. 
Common adjustment issues include misfed tubes due to incorrect carousel or loader 
settings, inaccurate fill amounts requiring adjustments to the filling mechanism, poor 
crimp seal due to inaccurate heights of the tube holder or dirty crimping surfaces and 
tubes jamming. 
The company currently has two different types of tube filling machines; they 
have three older Kalex® machines and one new IWKA ® Packaging system. Product 
X has been manufactured on both types of machines on separate occasions. The 
Kalex® machines have been used extensively for many years in the plant and the 
majority of employees are trained on the machines which can be run on all three 
shifts with only minor adjustments after the initial setup. Additionally, the Kalex® 
machines are less complex than the new IWKA ® machine and can be setup faster by 
the mechanics. The new IWKA ®system is only run by a select number of operators 
and generally runs during the 7:30am to 4:00pm shift, but will run longer to meet a 
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deadline if the operators are available. The Kalex® machines are capable of 
producing 35 tubes per minute of product X using two to three operators. The 
1WKA ® system can produce 70 tubes per minute using between two and four 
operators. Data collected during the filling of product X is presented in table 3, with 
both value added and non-value added time. 
Table 3. Data for Tube Filling Batch #3 
Tube Value Added Non Value 
Fillin_g_ Action 
_{_Minl Added_{_Minl 
IWKA Chan_g_e Over 300 
8:45 Start 45 
9:30 Break 20 
9:50 Start 5 
9:55 Sto_Q Mechanic adlust 5 
10:00 Start 2 
10:02 Sto_e_ Cleanin_g_ 1 
10:03 Start 5 
10:08 Stop_ Tube Loadin_g_ 4 
10:12 Start 1 
Not Sealing 
10:13 Sto_e_ P ro_Q_er!Y_ 1 
10:14 Start 1 
10:15 Sto_2._ Adiustments 1 
10:16 Start 7 
10:23 Sto_£ Fill Adlustments 3 
10:26 Start 19 
10:45 Sto_J.)_ Cleaning_ 2 
10:47 Start 1 
10:48 Sto_£ Fill Aqj_ustments 2 
10:50 Start 11 
11 :01 Sto_Q Aqj_ustments 7 
11 :08 Start 4 
11 :1 2 Sto_Q_ Crim_£ Defects 7 
11 :1 9 Start 34 
11:53 Sto_Q_ Cleanin_g_ 7 
12:00 Lunch 30 
12:30 Start 12 
12:42 Sto_Q_ Ho__i:>_Q_er Overflow 8 
12:50 Start 107 
2:37 Sto_2._ Cleanin_g_ 3 
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2:40 Break 15 
2:55 Start 58 
3:57 StoR Cleanin_g_ 3 
4:00 Break 12 
4:12 Start 7 
4:19 St OR Jam 1 
4:20 Start 80 
6:40 StqQ_ Job Com_E!ete 399 432 
Regardless of the filling machine used, a QC inspector must monitor the fill 
weights of five random tubes every half hour. A calibrated balance is kept within six 
feet of the filling machine and is used to weigh the tubes. If one of the tubes does 
not meet the weight specification, there must be an adjustment and five more tubes 
are tested. If tubes are not able to be brought into specifications, the machine is 
stopped for further adjustments and testing. Tubes manufactured during this time are 
weighed individually to determine if they are within specification, if they fall outside 
of a +/- 10% range, they must be rejected. This in-process testing aims to minimize 
the number of out of specification products that are produced. Although this system 
is relatively crude and does not adhere to statistical process control ideas, it does give 
QC an indication of gross errors. 
Operators are responsible for loading empty tubes into the chamber to ensure 
a continuous supply of tubes for filling. The hopper is fed with formulated material 
by operators periodically adding the bulk drug through the transfer pump from the 
storage vat. The hopper has been overfilled by accident, especially when the 
machine is run with fewer operators. This error requires operator cleanup, machine 
shutdown and wasted bulk product. 
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After tubes are filled and crimp sealed they are ejected from the machine and 
inspected by operators. Each tube must be squeeze tested and visually inspected to 
ensure a visible lot number and expiration date. If a tube fails either of these criteria 
it is thrown into a rejection tote which generally consists of <l % of total production. 
If the tube passes the inspection criteria, it is put into a plastic storage tote on a 
pallet. 
Each pallet holds up to 20 plastic totes, and the company owns 52 totes. 
When the totes are full, boxes are assembled (boxes are later reused for other 
products) by operators and filled in place of totes if the next process, cartoning, is not 
yet running. This occurs when the slower machine is used because the cartoner runs 
at a significantly higher rate and they want to prevent machine starvation. Therefore, 
the batch is completed to build up inventory and stored near the cartoning machine 
until it is ready to be cartoned. In contrast, they have overlapped the IWKA ®and the 
cartoning machine with a buildup of approximately 6,000-8,000 tubes of WIP and 
were able to reuse totes and avoid using cardboard boxes for WIP storage. 
5.2.3 Cartoning of Product X 
A mechanic must setup and adjust the Jones® cartoner to accommodate the 
size of the carton, the feed rate of cartons into the machine and the tape machine (a 
subsystem of the Jones® cartoner) to fit the different cardboard box sizes. 
Additionally, the mechanic must setup the machine to produce an accurate and 
visible lot number and expiration date. A QC inspector must check and document 
that the lot number and expiration date is correct and visible prior to beginning 
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cartoning. Before production begins, three to four operators assemble large 
quantities of preprinted cardboard boxes which are readily available to be filled with 
cartoned product. 
Cartoning occurs at a load rate of 78-82 cartons per minute. The machine can 
operate through all three shifts and run with between six and eight operators. 
Cartons are manually loaded by the supervisor into the feeder, which then is 
automatically loaded onto a conveyor which opens the carton. The opened carton 
travels around a circular track and two or three operators manually drop filled tubes 
of product into the open cartons. The filled cartons are then closed while in the 
cartoner and collected into groups of six after exiting the machine by an operator. 
The groups of cartons are then covered in plastic by a Shanklin® seal wrapper 
machine by an operator before being sent through the Clamco ® heat sealer. An 
operator fills the plastic sealed packs into cardboard boxes, which are then sealed 
with a 3M® taping machine. Taped boxes are placed on pallets and taken to the 
Lantech® pallet wrapper. Finished goods are placed in the production holding area 
under quarantine to await final assay results and reconciliation of quantities. The 
product may be moved via an internal shipping truck to the warehouse facility to 
await final shipping release if the QC operator has documented the quantity 
produced. Time studies collected during cartoning of product X is presented in table 
4, with value added and non value added time described. 
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Table 4. Jones Cartoner Data Collection for Batch #3 
Value Added Non Value Added 
Carton er J_Min)_ J_Min)_ 
Chan_ge Over 240 
Building Boxes 120 
4:20 Start 8 
4:28 Sto_I>_ Catchin_g u_Q 2 
4:30 Start 31 
5:01 St~ Ac!i_ustments 2 
5:03 Start 22 
5:25 St~ Catchin_g l!2. 1 
5:26 Start 14 
5:40 Stop Fixing 6 
5:46 Start 74 
7:00 Sto_I>_ Dinner 30 
7:30 Start 42 
8:12 Sto_Q_ Adjustments 2 
8:14 Start 46 
9:00 Sto_Q_ Break 15 
9:15 Start 22 
9:37 Sto_Q_ 3 
9:40 Start Fixing 35 
10:15 Sto_I>_ For NJg_ht 
Next 
DC!l, 
5:45 Start 75 
7:30 Stop Break 15 
7:45 Start 60 
8:45 StoQ_ Job Complete 454 436 
Total 
5.2.4 Current State Value Stream Map 
Data for the current state map of the system for product X at XYZ Pharma 
was collected through time studies and is presented in Tables 1 through 4. 
Additional data was retrieved from the master batch records of four recent 
production runs of Product X, as shown as in table 5. Uptime percentage was 
calculated by dividing the value added time (of the batch) by total production time, 
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both value and non value added. Non value added time was comprised of breaks, 
lunch, machine breakdowns and setup/change over times. Table 5 compiles data 
from four batches of product X. The batches of the first two columns were filled 
with the slower filling machine and waiting times designated as * *, were not 
included because they are not accurate representations of the system when the newer 
machines are used. Additionally, one of data points for vat storage designated as *, 
was not included because it was unusually long. 
Table 5. Overview of Batch Records of Product X 
Kai ex Kai ex IWKA IWKA AVG Std Dev 
Batches 1 2 3 4 
Formulation/mill 
Time 520 524 505 535 521 12.4 
Storage in Vat 11805* 1110 4965 3945 3340 1997.4 
Filling Time 998 1055 525 465 495 308.7 
Filling Scrap 
(%) 0.2 1.9 0.9 3.2 1.3 
Time Waiting 
for Carton ** ** 360 150 255 148.5 
Cartoning Time 545 530 470 480 506.25 36.8 
Cartoning Scrap 
(o/~ 1.64 0.6 0.5 0.3 0.76 0.6 
Wait Time To 
shiQping 900 3330 2715 2315 1263.4 
Total (Min) 4121 10,156 8294 7433 
Total (Hrs) 68.68 169.27 138.23 123.88 
The current state value map, shown in figure 11, gives the cycle time (CT) of 
an individual tube through processing, except during formulation where the batch is 
undergoing value added work at the same time. The map shows that the greatest 
wastes of time are the buildup of WIP in the systems before the filling line and after 
the cartoning process, where finished goods pallets are stored until the entire batch is 
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complete and ready for shipment. The lead time of the system was calculated to be 
7925 min and 50 sec. When divided by the total amount of operational hours from 
5:00am to 10:30pm (17.5 hours) the lead time is roughly 7.5 days. The current state 
is based on a five day work week, with Saturday and Sunday as days off. This 
translates into a "real world" lead time of 9.5 calendar days for one batch. An order 
for this product generally consists of three batches requiring minimal inter-batch 
changes, resulting in decreased holding times to avoid starving down process 
machines. Therefore the second and third batches are produced faster, and the entire 
three batch process requires approximately 11 days of processing or 15 calendar 
days. 
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Figure 11. Current State Value Stream Map 
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5.3 Development of the Pro Model® Simulation of Current State 
The ProModel® simulation utilizes collected data presented m tables 1 
through 4 and compiled master batch records, table 5, to create a model which 
depicts the current state of the system. All processing times, waiting times, and 
personnel assignments have been created through observation and verified through 
company documentation. A full text version of the model can be found in Appendix 
III. Figure 12 shows the layout of the facility and where the locations have been 
built. The flow of materials follows the current stream value map in figure 11 and 
the schematic material flow in figure 10. 
5.3.1. Current State Model Assumptions 
1. 1st shift (5 :OOam - 2:00pm) is comprised of operator_ I and 
material handler I. 
- -
2. 2nd shift (7:30am- 4:00pm) is comprised of the manufacturer, mechanic, 
driver and operator. 
3. 3rd Shift (2:00pm- 10:30pm) is comprised of operator_2 and 
material handler 2. 
- -
4. The Truck Driver has the sole responsibility of (un)loading the truck. 
5. Shipments of raw ingredients arrive on one truck and are of sufficient 
quantity to manufacture three batches for a total of 30,000 tubes of Product 
x. 
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6. Raw ingredients are taken directly to the manufacturing area, excess is first 
stored in the formulation holding area and the remainder is kept in the 
production warehouse area. 
7. Each batch of formulated bulk requires 2 pallets of Raw_Ingredients_Drum 
and 2 pallets of Raw_ Boxed_ Ingredients to be combined. 
8. After a batch of formulated bulk drug has been removed, the manufacturer 
immediately begins the next batch without a setup, until all batches have been 
formulated. 
9. Mechanic setups of the filling machine begin after the stored bulk drug vessel 
has been brought to the filling area. 
10. Filling using the IWKA ® machine is completed by the "operator", which 
consists of three operators specially trained on the machine who only work 
during the second shift (7:30am - 4:00pm). 
11. The filling machine fills 84 WIP totes, which contain 375 tubes per tote to 
account for a small batch overage. 
12. Mechanic setups of the cartoning machine begins after the entire batch of 
tubes has been filled into WIP totes and moved to the Jones® WIP feed area. 
13. The Jones® cartoner can be run by either operator_! or operator_2 which 
both consist of 7 operators each and operate in the first and third shifts 
respectively. 
14. Finished goods are packed into 72 count boxes before they are palletized as 
70 boxes to a pallet. 
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15. Material handling is performed by one material handler during the first shift 
and a designated material handler during the second shift which is normally 
an operator or supervisor. 
16. Each completed batch yields 6 pallets of finished goods inventory. When 6 
batches are completed, the QC reconciliation process begins prior to 
shipping. 
69 
......i 
0 
Figure 12. Current State ProModel® Simulation Layout 
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5.4 Chapter Review 
This chapter introduced XYZ Pharma as a manufacturer and described the 
system required to produce Product X. Data collected through time studies and 
master batch records were presented to give the reader an understanding of how the 
product is currently manufactured. The current stream value map helped in the 
identification of problematic areas throughout the system. The results of the current 
and altered future state ProModel® simulations are presented in the next chapter. 
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Chapter 6 
6.0 Results 
This chapter will present possible areas for improvement to the current 
system based on the ProModel® simulation and current stream value map. Three of 
these areas for improvement are modeled in a future state. The primary study, 
metric, that was chosen, was the minimization of throughput time to improve 
meeting deadlines for contract customers. The results of these future state 
simulations were analyzed for statistically significant factors and interactions. 
6.1 Results of the Current State ProModel® Simulation 
The data tables presented are separated into two groups: inventory and 
transfer holding locations and equipment locations. The equipment locations are 
areas that processing of WIP occurs, while the inventory and transfer holding 
locations are all of the supporting locations for the manufacturing systems. Table 6 
shows the results of the current state simulation to gain an understanding of the 
steady state of the system. Unlike the value stream map, the simulation runs 
overnight and on the weekends, to describe a more realistic picture. The calculated 
average throughput time through the system for 999 replications of the simulation 
was 370.92 hours or 15.45 days. In order to ensure that the simulation adequately 
represented the real world conditions the average time per batch, 123.88 hours (from 
table 5), is multiplied by three to give a total order time of 371.65 hours. The 
average time from the simulations is divided by the average time from the master 
batch records and is 99.8% similar. It is important to consider that time value is 
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averaged and does not account for overlapping production of batches which may 
occur. 
The IWKA® filling machine has the highest percent utilization of processing 
equipment while the pallet wrapper has the lowest. The largest periods of non value 
added time are when the operation waits to batch. The time the formulated bulk drug 
product spends in the transfer vat waiting to be brought to the filling line is very 
long. Also the time spent waiting for the batch of wrapped and palletized finished 
goods is considerable. Due to the infinite capacity of the production warehouse area 
in the model, the utilization percent is not calculated, this was purposely avoided to 
prevent blockage of incoming, outgoing and stored materials which would require a 
separate in depth material handling study out of this project's scope. 
Table 6. Results of the Current State ProModel® Simulation 
Location Name Avg Time Per Entry (MIN) % Utilization 
Inventory Transfer and 
Holdif!K 
Production Warehouse Area 3081.99 0 
Formulation Holdin__g_ Area 934.16 12.79 
Storage Vat Load 977.77 13.39 
Vat Holdin_g Area 7097.92 31.64 
IWKA WIP Holding 54.86 0.64 
Jones WIP feed 353.97 4.06 
Jones FGI 203.02 14.32 
E.!l_uipment 
Lee Kettle 1397.93 19.14 
IWKA 1816.03 24.58 
Jones Cartoner 142.85 16.49 
Pallet Wr'!££er 27.14 2.26 
Total System Throughput 
Time 370.92 hrs 15.45 days 
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The average time per entry (min), is the average time an entry spends at a 
location. The utilization percentage is defined as the percentage of capacity 
occupied. The utilization percentages appear lower than the uptime calculated by 
hand for the current stream map because physical capacities were not always fixed or 
clearly defined. The simulation calculates utilization over the course of the entire 
run and is different from the value stream map which calculated the uptime for each 
machine to process the first unit of the product. For the production warehouse area 
an infinite capacity was assigned to prevent the blockage of incoming or outgoing 
material; therefore, there is no calculation of the utilization %. 
Table 6 shows that the two highest utilization percentages of equipment or 
inventory transfer and holding are the vat holding area and the IWKA ® filling 
machine, respectively. These areas appear to be bottlenecks in the current system 
and should be viewed as areas for improvement for the future state. While the 
production warehouse area does not have a calculated utilization percent, the average 
time per entry is the second highest and should also be considered as a potential area 
for improvement. 
6.2 Areas for Improvement 
All of the areas for improvement suggestions considered in this paper are 
from an efficiency approach. cGMP's must be followed for each product and 
manufacturer considering changes. Experimentation and validation may be required 
to implement the proposed changes. The FDA and appropriate regulatory documents 
should always be consulted if there is uncertainty in a regulatory area. 
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6. 2.1 Quality Control 
6.2.1.l Testing 
Testing bulk at the same time as finished goods is double end product testing. 
This is a common practice where management is confident that its process will result 
in an accurate product because it has been rigorously validated, but it does leave the 
company vulnerable if the assay fails because many tubes have already been filled by 
this point. A bulk drug product can be "reworked" to meet specifications if a 
deviation report is filed, but once the product is filled and crimped into tubes, it is far 
too labor intensive and cost prohibitive to empty each one for rework. 
6.2.1.2 JIT QC 
The quality control department is responsible for reconciling (counting) all 
materials that have been used, defects produced and finished goods for release. The 
majority of finished goods may not be released from "quarantine" until the product 
has successfully passed shipping release testing for quality and QC reconciliation to 
meet FDA requirements. Finished goods can be shipped under "quarantine" if the 
reconciliation documents have been completed for the materials shipped and a 
sample has been taken for testing. Upon successful testing of the product, the 
customer is faxed confirmation of the test results and the product is removed from 
"quarantine." This practice would shorten lead times and could be considered for 
low risk products to ensure that a batch is not defective. Often the QC inspector will 
wait until the entire batch is completed before counting the finished goods inventory 
and compiling the final batch release documentation. Due to space limitations in the 
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production facility warehouse, quarantined finished goods may be moved to the 
larger warehouse building until they pass shipping release parameters. 
Unfortunately, the QC inspector is often unaware if a pallet of quarantined finished 
goods has been moved to the other building and can cause delays and errors during 
reconciliation. Conversely, if the inspector does count a portion of the finished 
goods and they are available to be moved to the main warehouse, it will not be 
moved by the material handlers unless the warehouse supervisor instructs them. By 
having the QC inspector keep an ongoing count of finished goods pallets as they are 
produced and placing a marking such as a neon sticker onto the pallets, the material 
handlers will know to put the pallets on the milk run truck. This will free up space in 
the production warehouse area and decrease the time required for reconciliation after 
production is complete. 
6. 2. 2 Deliveries 
"Milk-Run" Truck Efficiency Improvement 
Currently the "milk run" truck runs between buildings approximately every 
one and a half to two hours. The truck is not always full, and leaves the production 
facility empty on its last run at 4:00pm. This is surprising considering the production 
building warehouse is normally very congested and items are usually blocking each 
other. Cardboard generated during manufacturing can be found throughout the 
facility and is only removed occasionally. Excess raw ingredients and components 
often stay in the production warehouse area for a few days after they could have been 
removed. By utilizing the proposed QC improvements above, the truck will have 
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excess material to load throughout the day and can fill the truck more often. Storing 
the truck at the production facility overnight will allow late shift employees to place 
materials directly into the truck and avoid the production warehouse area completely. 
6.2.3 Inventories 
6.2.3 .l Decreasing Storage Vessel Batch Sizes 
The steps involved in the formulation of bulk drug can not easily be changed, 
as the process has been given by the customer and validated by XYZ Pharma. A 
significant change in the formulation would require revalidating the process for the 
FDA. This product is relatively complex and requires many processing steps, many 
of which have been developed with current batching equipment in mind. Until 
development of continuous formulation methods and equipment improve, the 
product is not currently a strong candidate to make the transition from batching. 
However, after the bulk drug has been formulated, there are opportunities to decrease 
the batch sizes of the WIP in the system. Currently, all 877 Kg of the bulk drug is 
milled directly from the Lee Kettle® to a large stainless steel transfer vat. This 
process takes an average of two hours and the transfer vat is then available for the 
mechanic to prime the next process, the filling machine and complete the setup 
process. The transfer vat is on wheels and is moved by the manufacturing specialist 
to the storage area while the mechanic moves the transfer vat to the filling machine 
and must be carefully navigated through the production facility. The stainless steel 
transfer vat could be replaced with four 55 gallon drums, fitted with a non reactive 
plastic liner validated to avoid chemical reactivity and degradation. The drums have 
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capacities of 225 Kg each which would allow the mechanic could complete the 
filling machine's setup, and begin filling an hour and a half sooner. Each drum 
would contain approximately 25% of the quantity of the transfer vat, and could be 
filled in half an hour. The drums are individually transported with a drum dolly by 
material handlers or the mechanic and are more maneuverable, occupying far less 
floor space than the transfer vat. The viscosity of product X allows direct transfer 
from the drum to the hopper via a compressed air pump and would free up a transfer 
vat, which are often in short supply. 
6.2.3.2 Decreasing WIP Buffers 
Currently tubes are filled with product X and then put into plastic totes. 
Totes contain an average of 375 tubes and are stacked 20 totes to a pallet. Full 
pallets are then removed from the filling area and are stored near the next machine, 
the cartoner. The cartoner is not started until filling is complete or very near 
completion. This buildup in WIP is in response to the cartoner running slightly 
faster than the filling machine. The cartoner loads 80 cartons per minute, each 
carton is filled with one tube of product X, while the IWKA ® filling machine loads 
70 tubes per minute. The filling machine generates a new WIP tote every 5 minutes 
and 21 seconds and the cartoner consumes 1 WIP tote every 4 minutes and 30 
seconds. If one WIP tote was delivered to the cartoner every six minutes, to account 
for travel time, the cartoner would run at a deficit of 1050 tubes per hour, if the 
system ran optimally at 80 cartons per minute. The current average wait time 
between finishing the filling process and beginning the cartoning process is 255 
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minutes. If a one hour buffer of 4200 tubes was generated while the cartoner was 
finishing its last hour of its four hour setup and a newly completed WIP tote was 
brought every six minutes, the cartoner could run for four hours. Regardless of the 
time of day, there is a 15 minute break every two to two and a half hours, and a 
lunch/dinner break every four to four and a half hours. If more operators were 
trained on the filling machine, they could keep the machine running during the two 
15 minute breaks and 30 minute lunches to create new buffers, while the operators 
on the cartoner shut down during their breaks. This coverage through breaks would 
result in 1050 tubes during break periods and 2100 tubes during lunch for a steady 
replenishment of the buffer stock to ensure smooth production. 
6.2.4 Facilities 
6.2.4.1 5s for Facility 
FDA regulations require that the manufacturing areas be clean (shine) and 
follow SOP's (standardize), which leads many in the pharmaceutical industry to feel 
that only the remaining 3s applies. Storage areas are less strictly monitored and 
XYZ Pharma is in dire need of a 5s plan for its production warehouse area. 
Although the wall does contain signs to indicate where incoming and outgoing 
material belongs, it is rarely followed due to the lack of free space. There are pallets 
with materials that do not belong there which should be returned to long term storage 
or other locations. There are no markings on the floor to alert material handlers 
where materials can safely be stored without obstructing walkways. Material 
handlers waste movements when they must repeatedly move materials to access 
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blocked pallets. Usually materials that are blocked tend to be left in the storage area 
long after they have been used or needed, which may be considered an inappropriate 
long term storage area by the FDA. 
Sort: By evaluating the contents of the current production warehouse area and 
removing unnecessary materials, the flow of the product will be greatly improved. 
Stabilize: Creation of designated "homes" for raw materials, finished goods, pallet 
trucks, recyclables, etc. will facilitate the rapid identification of materials that are out 
of place or in need of attention. Shine: All of the cardboard boxes and empty 
material drums should be removed and the loading dock and production warehouse 
area should be power washed. Standardize: Create standard operating procedures, 
which are based on visual information, such as simple diagrams and cartoons to 
indicate the proper method to store and remove material. Create a regular schedule, 
every three to four days, for empty drum removal. Sustain: Create a reward system 
for maintaining the area and following the standardized work. Incorporate cleaning 
and organization into employee's jobs, and utilize down times to ensure the work 
place is maintained. 
6. 2. 5 Equipment 
6.2.5.1. Visual controls to decrease setup times 
Incorporate visual control techniques into the equipment and manufacturing 
areas. Use shadowboards for mechanics tools and for parts used in equipment setups 
(tubes, valves). Some setups have over 50 individual components that are placed on 
a moving cart where QC inspects them, but QC is unable to identify whether parts 
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are missing or in excess. If parts are missing, the setup process is disrupted and 
results in the mechanic having to track down the proper tool or part. Additionally, 
manufacturers can easily assemble kettle components, such as rubber blades of the 
sweep mixer incorrectly, which can have severe impact on the product. While the 
manufacturers and mechanics are highly trained, these suggestions would benefit 
new employees being trained and help the current staff avoid errors. These measures 
would facilitate cross training of employees and give more employees a broader 
system's perspective. 
6.2.5.2. Autonomation 
The incorporation of autonomation to a number of locations at XYZ Pharma 
would result in improved product quality and fewer operators needed on machines. 
Currently, the beverage industry commonly uses online sensors to monitor filling 
rates and accuracy during production, thereby removing the need for end product 
content uniformity testing which is currently a time consuming and labor intensive 
FDA requirement (Jeffries, 2003). The addition of online sensors to the filling 
machines at XYZ Pharma would allow operators more freedom to attend to other 
tasks and decrease the total number of operators required. These operators could be 
reassigned to other areas or serve to cover break periods. 
Specifically, the IWKA ® is pre-wired but not equipped with a sensor to 
monitor the loading of empty tubes. The sensor would automatically shutdown the 
machine in the event of a misfeed or a tube jam. This is a common problem which 
currently requires an operator to monitor tube feeding. The hopper is also 
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susceptible to bulk product overflow, where currently a mirror is the only equipment 
used to monitor the fill height. Ultrasonic sensors have been employed for a number 
of years by biotechnology, oil, food and other industries for processing monitoring 
and control, automotive techniques and chemical analysis. (Hauptmann, 1998) 
These sensors have evolved into low cost tools which could monitor hopper fill 
levels, as well as monitor the bulk material viscosity and homogeneity for enhanced 
online monitoring. 
6.2.6 Personnel 
6.2.6.1. Cross Training Personnel 
The current training of operators is performed on the job. Most operators are 
trained on two to three pieces of equipment and rotate when needed. While job 
rotation is performed, it could be expanded. The new IWKA ® filling machine is 
operated by a select team of operators and is limited to one shift. By increasing the 
number of operators that can run the machinery, the overall processing time could be 
increased. As there is a surplus of operators, and often slow periods are used to build 
boxes for later use, training could be accomplished during these points. Also, by 
creating a rotating team of cross trained employees to cover break and lunch periods, 
machines would remain operational and keep pace of production at a level pace. An 
additional mechanic for the third shift is required to setup and maintain the filling 
machinery, which they are currently in the process of training. 
Additional areas for cross training could include cleaning responsibilities. To 
alleviate both the mechanics and the manufacturers, operators could rotate into the 
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cleaning area to sanitize equipment parts during changeovers. This would decrease 
waiting times and give mechanics and manufacturers greater time to use their skills 
for specialized tasks. There are only two manufacturing specialists currently 
operating 5 days a week. Cross training other employees in basic areas of the 
manufacturing specialist's responsibilities such as prep work, setup and changeover 
would also give the manufacturing specialist more time. If a manufacturing 
specialist is sick, their manufacturing area is not used which results in greater 
product lead times. Training additional personnel to formulate would alleviate 
problems arising from unexpected work absences, as well as increase the capacity to 
produce during the weekend. 
6.2.6.2. Off shift personnel 
In addition to cross training employees, off shift personnel could decrease a 
significant portion of non value added time that is currently experienced. A small 
team of personnel could perform a number of tasks during non operational hours 
(10:30pm - 5:30am) to improve flow during operational hours. Cleaning would be 
the primary responsibility of the team. Areas would include cleaning formulation 
kettles, parts for equipment setups, empty raw material drums and the facility itself. 
Material movement would be the other focus, such as cardboard for recycling, 
components for return to the production warehouse area and raw materials for 
production the next day. The truck for inter building deliveries could be stored at the 
production facility loading dock and loaded throughout the night in order to remove 
unneeded materials. 
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6.3 Development of the Future State ProModel® Simulation 
Table 7. 23 Factorial Design of Three Factors Selected for Experimentation 
Factors 
Runs A B c 
1 0 0 0 
2 0 0 1 
3 0 1 0 
4 0 1 1 
5 1 0 0 
6 1 0 1 
7 1 1 0 
8 1 1 1 
Factor A is the addition of the Kalex® filling machine. This machine is 
operated by three operator teams during the first and third shift, with a total of 17 
hours of available manufacturing time. This machine operates to the specifications 
given in the description of the filling process of product X. If there is no cross 
trained operators available, they are pulled from available Operator_ 1 or Operator_ 2 
groups. If there is no change in the batching rules, the new machine will feed the 
current IW AK_ WIP _Holding area and is moved when 21 WIP Totes have been 
accumulated from the two machines on the shared pallet. 
Factor B is the cross training of personnel. By training operators on all of the 
machinery, work assignments are made from a general pool of available operators 
and can cover all the hours of operation on all machines. Additionally, material 
handlers have been given the option of assisting the mechanic in the movement of 
hulk drug materials and the driver to move raw ingredients and finished goods. 
Mechanic_ 2 has been trained for the third shift, while the fust mechanic has been 
moved from the second to the first shift. In the case of a cross training scenario 
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without the addition of the second filling machine, the 3 dedicated operators from the 
IWKA ® will be cross trained and distributed. Operator_ I and operator _2 will each 
gain one operator and have 8 each; the odd operator will be removed and considered 
reassigned. 
Factor C changes the batching rules during production. First, bulk drug 
substance is no longer transported in one large transfer vessel. Formulated bulk is 
now divided into four 55 gallon drums and transported individually to the filling 
machines. WIP totes created after filling the product into tubes are no longer 
batched 20 totes to a pallet prior to transfer to the cartoner. Instead, the totes are 
moved by any available operator or material handler after each tote is filled. Totes 
can be moved on wheeled carts by anyone and no longer require pallets or jacks to 
move them. Final QC reconciliation is no longer performed after all of the finished 
goods pallets have been completed. Additionally, the finished goods pallets are 
moved out of the production warehouse area after they have been reconciled and are 
shipped to the customer from the warehouse building. 
6.3.1 Assumptions of the Future State ProModer Simulation 
1. 151 shift (5:00am 2:00pm) 1s comprised of the mechanic, 
material_ handler_ 1, and operator_ I. 
2. 2"d shift (7:30am- 4:00pm) is comprised of the manufacturer and driver. 
3. 3rd shift (2:00pm lO:OOpm) is comprised of mechanic_2, 
material_handler_2 and operator_2. 
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4. The "operator" group has been reassigned and operator_! and operator_2 
consist of a pool of 10 operators each. 
5. 2 pallets of Raw_ Ingredients_ Drum and 2 pallets of Raw_ Boxed_ Ingredients 
are delivered in each arrival and are brought directly to the manufacturing 
area. Excess is only stored in the formulation holding area. Additional 
arrivals are triggered when the formulation holding area is emptied by the 
manufacturer as a pull system. 
6. Completed formulation of bulk drug is transferred with milling to four 55 
gallon drums, capable of transporting up to 225 kg each, named 
Bulk_Drug_ Wip_l. 
7. When a Bulk_ Drug_ Wip _ 1 drum is filled, it is moved to the hopper by 
material_handler _ 1, material_ handler_ 2, or the mechanic. 
8. The hopper location serves to split the Bulk_Drug_ Wip_l into 21 parts, 
which are routed to the first available Kalex _ 2 or the IWKA filling machine 
by Operator_ I or Operator_2. 
9. Kalex _ 2 and IWKA filling machines are operated from a pool of 10 general 
operators during the first and third shifts. 
10. An operator from the Kalex_2 and IWKA filling machines move WIP totes 
as soon as they are filled and are not batched. 
11. When the first WIP tote arrives from either filling machine, the Jones 
Cartoner® setup begins. 
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12. FGI_Pallets are reconciled by QC individually as they are placed into the 
production warehouse area. Upon reconciliation, they are removed by the 
"milk truck" to the main storage area or are shipped out to customers. 
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6.4 Results of the ProModel® Simulations 
Table 8 and figure 13 show the average throughput times of 999 simulation 
replications for each of the eight ProModel® scenarios. Scenarios 4 and 8 show the 
greatest improvement over the original current state throughput time. Scenario 8 is a 
future state with all three factors changed, which is comprised of parallel machining, 
cross training and changing the batch rules. Scenario 4 is the same as scenario 8, 
except it does not use parallel machining methods. Scenario 5 only utilizes parallel 
machining and is considerably worse than the original current state, scenario 1, 
which demonstrates the importance of personnel and a support system to enhance 
manufacturing. 
Table 8. Rounded Average Throughput Times (Hr) of all ProModel® Scenarios 
Scenario 1 2 3 4 5 6 7 8 
Avg. 
Throughput 
(Hr) 371 189 284 105 406 161 290 110 
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Figure 14. Average Throughput Time for all ProModel® scenarios 
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Table 9 compares all of the ProModel® scenarios and depicts the average 
time per entry, which gives the average time spent by each component traveling 
through the system for a given location in minutes. This table is helpful to evaluate 
the effects of changes in scenarios on processing and holding times. It is important 
to consider that when batch sizes change, there are a different number of entities in 
the system and some locations are avoided all together. Therefore, this table is most 
useful to compare scenarios with similar factors and graphs are used to illustrate 
important differences. 
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Table 9. Average Time Per Entry (Minutes) of all ProModel® Scenarios 
Location Name 1 2 3 4 5 6 7 8 
Inventory Transfer 
and Holding_ 
Production 
warehouse Area 3082 598 2242 164 3061 629 2198 136 
Formulation 
Holdin__g_ Area 934 1584 943 1458 939 1076 939 1140 
Storage Vat Load 978 631 986 154 979 119 980 87 
Vat Holding Area 7098 0 4537 0 8912 0 5021 0 
IWKA WIP Holdin_g_ 55 0 97 0 304 33 235 1 
Jones WI P feed 354 11 493 33 1127 207 785 171 
Jones FGI 203 226 132 99 222 235 126 171 
E!E!ipment 
Lee Kettle 1398 3266 1411 1909 1404 1560 1404 1576 
Hopper 0 658 0 147 1262 385 734 112 
IWKA 1816 33 1021 9 46 31 22 9 
Kalex 2 0 0 0 0 44 27 32 20 
Jones Cartoner 143 117 112 63 172 142 118 75 
Pallet Wra.EE_er 27 22 31 25 26 40 41 169 
Figures 15 and 16 compare the effects that changing batching rules has on 
raw ingredient storage. Interestingly, time spent in the formulation holding area 
which is directly adjacent to the manufacturing area is about 400 min greater on 
average for the continuous processing models. This increased holding time in the 
area may appear to be a negative finding for decreasing batch sizes, but in effect the 
amount of time materials spend in the production warehouse area will decrease the 
overall inventory and clutter. Raw materials are spending more time in the area 
designated for them, instead of a general "dumping area" which occurs currently for 
raw materials when the formulation holding area is full. By decreasing the amount 
of materials that are delivered to meet the formulation requirements for the day, they 
are decreasing the necessary time to move materials multiple times. This decreased 
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material movement is particularly true when materials are blocking other items that 
are needed and must be moved to access them. 
The effects of changing the batching rules to a more continuous approach 
additionally impact the outward flow of finished goods. The batch methods store 
materials longer in order to create a batch and subsequently cause a buildup of 
inventory in the production warehouse area. Figures 15 and 16 group the average 
time spent per entry of raw materials and palletized finished goods together for both 
the traditional batch processing scenarios and the future state batching rules. The 
differences in the approaches yield considerable time savings, occupying the 
production warehouse area for approximately 50% less time. This can be accounted 
to the JIT QC approach, which would reconcile the finished goods as they are 
completed and would be removed by one of the "milk runs" or outside shipper. 
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Figure 15. Raw Ingredients Holding Time for Batch Processing 
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Figure 16. For scenarios implementing more Continuous Processing 
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Figures 17 and 18 describe the effects changing the batching rules on the time 
WIP is held in the system. The two figures are on largely different scales, due to the 
long holding times experienced in the traditional batch process. The time the bulk 
drug product spends in the transfer vat holding area is extremely long. XYZ Pharma 
will often wait to batch and have three formulated transfer vats of Product X, ready 
for filling to avoid having to setup their filling machines multiple times. This results 
in large inventories of WIP, being held for a number of days. Other areas of WIP 
holding are also greatly decreased because the flow of materials has changed from 
pallets to WIP totes. The filling machine must no longer create an entire pallet of 
WIP totes prior to their transfer. Instead, as a tote is filled, it is transferred to the 
next station by any available operator or material handler. Additionally, material 
handlers are no longer necessary to move pallets of WIP totes and are free to assist 
other operations. 
Decreasing the amount of WIP in the system is an important goal of lean 
manufacturing. WIP crowds the plant's floor space and should be considered a 
liability. Since XYZ Pharma is a contract manufacturer they are not paid to 
manufacture WIP, but are paid for their finished goods. This lean thinking 
challenges the manufacturer to decrease the lead times in order to make more money. 
This methodology is in stark contrast to the traditional approach of a large WIP 
inventory, which may appear to be giving the manufacturer an economy of scale. 
Additional inventory in the system will hide problems such as defects, inefficiencies, 
long setup times and long lead times, while incurring the costs of storage and 
delayed lead times (Liker, 2004). 
94 
Figure 17. Holding Time for WIP in the System for Batch Processing 
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Figure 18. Holding Time for WIP in the System for more Continuous Processing 
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Figure 19 compares the average time per entry (min) that a box of finished 
goods inventory spends waiting after completion of operations at the Jones® 
cartoner. The time spent on the pallet waiting to batch for the final finished goods 
pallet is currently unavoidable. In an ideal setting, palletizing would be an 
unnecessary step and boxes would be shipped as soon as they had been completed 
and reconciled. Unfortunately, due to QC testing and customer requirements 
decreasing shipments to single pallets instead of individual or groups of batches, 6 
pallets each is the best approach. Scenario 4 spends approximately 50% of the time 
as the current state, scenario 1, while scenario 8 only reduces the average time per 
entry (min) by 15% of the current state. Additionally, scenarios 3 and 7 reduce the 
average time per entry by roughly 35% each. The common factor among these four 
scenarios is the cross training of employees. Since the IWKA ® filling machine is 
operated for two shifts in these scenarios, the probability that the Jones® cartoner will 
be waiting for material is reduced and time spent waiting to accumulate enough 
boxes to fill the pallets will be decreased. Cross training will result in more available 
material handlers, as they are assisted by the driver and operators in other areas of 
production. 
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Figure 19. Finished Goods Inventory across all scenarios 
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Table 10 shows the utilization(%) of locations in the model, which is useful 
to identify possible new bottlenecks created in the system after changes have been 
made. An increase in utilization can not automatically be described as a bottleneck. 
"A bottleneck is any resource whose capacity is equal to or less than the demand 
placed upon it. And a non-bottleneck is any resource whose capacity is greater than 
the demand placed upon it" (Goldratt, 2004). For example, a utilization of 99% does 
not constitute a bottleneck if it is able to meet demand. Fluctuations and variability 
in the system must be accounted for with excess capacity to prevent the formation of 
bottlenecks throughout the system. Therefore, the utilization can be used to identify 
locations for further investigation. Many manufacturers strive to reach high 
utilization rates for expensive machinery and research has shown that this can result 
in a large buildup of WIP in front of the machine to avoid starvation (Li, 2007). This 
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buildup of WIP has negative effects on the system and can be seen from the batching 
used at XYZ Pharma. 
Table 10. Utilization (%) of locations 
Location Name 1 2 3 4 5 6 7 8 
Inventory 
Transfer and 
Holding_ 
Production 
Warehouse Area 0 0 0 0 0 0 0 0 
Formulation 
Holdin_g_ Area 13 42 17 69 12 36 16 54 
Stor<!Q_e Vat Load 13 67 18 30 12 16 17 17 
Vat Holdin_g_ Area 32 0 26 0 36 0 29 0 
IWKA WIP 
Holdif!9_ 1 0 1 0 3 0 4 0 
Jones WI P feed 4 0 7 1 12 5 12 7 
Jones FGI 14 32 13 25 14 37 12 40 
Eg_up_ment 
Lee Kettle 19 86 25 91 18 52 25 74 
Ho_e_e_er 0 70 0 28 16 13 13 23 
IWKA 25 74 18 36 25 45 19 26 
Kalex 2 0 0 0 0 23 37 19 26 
Jones Cartoner 16 26 17 25 18 37 18 31 
Pallet Wrapper 2 3 3 7 2 8 4 45 
Figures 20 and 21 give a graphical representation of the effects of changes on 
the utilization of locations throughout all of the scenarios. Figure 20 shows the 
locations which are used for inventory transfer and holding. Increasing the 
utilization of holding and transfer areas is not the goal of lean manufacturing and 
implies that raw materials or WIP is occupying holding areas adding to non value 
added time. Therefore, utilization alone must not be misinterpreted and compared 
with figures 15 through 19, the overall holding time has been decreased in scenarios 
utilizing changes in batching rules. Subsequently, inventory is occupying holding 
and transfer areas for a greater percentage of time, but is occupying the locations for 
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shorter periods of time overall. In certain scenarios locations such as the transfer vat 
holding area, the IWKA ® WIP holding area, and the Jones® WIP feed area have all 
been avoided or reduced to negligible utilizations. 
Figure 21 describes the utilization (%) of the plant's processing equipment. 
All scenarios except scenario 5, showed increased utilization of the Lee® Kettle, 
regardless of the factors changed. The greatest increases in utilization of the kettle 
occur when the batching rules are changed, as can be seen in scenarios 2, 4, 6 and 8. 
The usage of drums to transport the materials results in down line processing 
beginning sooner. Because utilization is calculated as the percent of the location 
capacity occupied and little has been changed to alter the formulation procedure, 
other than the arrivals of raw materials, the same amount of formulation time appears 
as a greater percentage when the system throughput times are decreased. 
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Figure 20. Utilization(%) of Inventory Transfers and Holding 
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Figure 21. Utilization(%) Equipment 
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Scenario 4 has been identified as providing the lowest throughput time (Hr) 
out of the 8 tested scenarios. Following the continuous improvement philosophy, the 
next phase of improvements would address the new locations which have 
subsequently become bottlenecks in the system. The addition of cross training and a 
change in the batching rules has shifted the bottleneck to the formulation step. The 
utilization of the Lee® Kettle has increased from 19% to 91 %, which strongly 
suggests further improvements to setups, cleaning and removal of other non value 
added operations. If minimization of non value added time does not relieve the 
formulation bottleneck, parallel machining should be investigated. The inventory 
transfer and holding areas experience a large increase from the current state in 
utilization of the formulation holding area from 13% to 69%. Further improvements 
would consist of a more precise JIT system, which would bring the correct amount of 
materials for formulation at the time the manufacturer required them. The 
improvements in scenario 4 improve upon the current system by spreading out the 
arrivals of the raw materials, but inventory is still held in the formulation holding 
area. If this JIT system was instated, the current formulation holding area could be 
converted into a processing area, or other purposes. 
6. 4.1 Statistical Analysis of Results 
To determine whether the three factors and their interactions are significant a 
full factorial design was analyzed. The adjusted R2 value is defined as, "a statistic 
that is adjusted for the 'size' of the model, that is, the number of factors" 
(Montgomery, 2005a). The adjusted R2 value is correlated with the amount of 
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explained variability. Adjusted R2 was calculated to be .89, which indicates that 
model is expected to explain 89% of the variability in the data. This value is given 
in Table 11 , along with the unadjusted R2, number of observations and the root mean 
square error. The summary of fit and the lack of fit tests are statistical methods to 
determine whether there is an unacceptably high level of variability in the system 
due to factors which do not belong in the model. 
Table 11. Summary of Fit 
RS_g_uare 0.891288 
RS_ciuare A<ii_ 0.891207 
Root Mean S_quare Error 37.63837 
Mean of Re~onse 239.5579 
Observations 7992 
Table 12 shows that the calculated maximum R2, .896, is very similar to the 
summary of fit's adjusted R2 which indicates that the model does not have a lack of 
fit. The calculated P value is less than .05; therefore, the hypothesis that this model 
is adequate has less than a 5% chance of being rejected (NIST, 2006). 
Table 12. Lack Of Fit 
Source DF Sum of S_quares Mean Square F Ratio 
Lack Of Fit 1 491648 491648 362.7742 
Pure Error 7984 10820280 1355 Prob> F 
Total Error 7985 11311928 <.0001 
MaxRSq 0.8960 
Table 13 is the analysis of variance (ANOVA), "tells us whether there is a 
difference among means. It does not tell us which means differ" (Montgomery, 
2005b ). The P value is given as zero, which indicates that the difference in means is 
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statistically significant. In order to determine which factors differ and if it is 
significant the effects test was performed in table 14. 
Table 13. Analysis of Variance 
Source DF Sum of Squares Mean S_quare F Ratio 
Model 6 92742617 15457103 10911.05 
Error 7985 11311928 1416.6472 Prob> F 
C. Total 7991 104054545 0.0000 
Table 14. Effect Tests 
Source N_Qarm DF Sum of Squares F Ratio Prob> F 
Parallel MFG 1 1 40767 28.7772 <.0001 
Cross Train 1 1 14217695 10036.16 0.0000 
Batch 1 1 77386070 54626.21 0.0000 
Parallel MFG*Cross 1 1 1147 0.8099 0.3682 
Train 
Parallel MFG*Batch 1 1 514934 363.4881 <.0001 
Cross Train*Batch 1 1 582003 410.8311 <.0001 
The effects test in table 14 shows that all three mam factors, parallel 
manufacturing, cross training personnel and a change in batching are significant. 
The interaction between each of these factors is also examined by this statistical 
method. The interaction between parallel manufacturing, changing batching rules, 
the interaction between cross training personnel and changing the batching rules are 
both significant interactions. While the interaction between parallel machining and 
cross training are not a significant interaction. The non significant interaction is 
most likely due to the overpowering effect of changing the batching rules. Changing 
the batching rules has the strongest effect on the outcome which is demonstrated in 
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the prediction profiler, figure 22 and the Pareto chart, figure 23. This dominant 
factor effect results in significant interactions with the other factors. 
Figure 22. Prediction Profiler of the Factors 
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Even though all of the factors and interactions except one, parallel 
manufacturing and cross training, are statistically significant, that does not imply that 
they all have the same effect on the outcome. Figure 22 shows parallel 
manufacturing having virtually no effect on the throughput time, while cross training 
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and batching changes have greater impacts. Figure 23, the Pareto chart, quantifies 
and ranks the effects of each of the terms and interactions. 
6.5 Future State Value Stream Map 
The future state value stream map was created based upon results found from 
scenario 4. This scenario yields the lowest simulation throughput time which is the 
primary goal for a contract manufacturer. In contract manufacturing overproduction 
is not a concern because company XYZ Pharma only produces what their customers 
have ordered. This scenario utilizes cross training and change in batching rules to 
decrease lead times. Differences from the current state with regard to cross training 
are the increase in shifts that are available for the IWKA ® filling machine to operate, 
due to a greater number of operators able to run the machine. The most significant 
factor that was found through the statistical analysis was the batching rule changes. 
These changes affect the entire process from arrivals to departures of finished goods 
inventories. Arrivals of raw ingredients are limited to quantities required for 
formulation of bulk drug at that time and are stored directly outside of the 
manufacturing areas. The replacement of the transfer vat with more flexible and 
mobile drum has decreased waiting times during transfers and setups, subsequently 
decreasing the cycle time by approximately 90 minutes. Another benefit of earlier 
bulk drug substance arrivals are the completion of final adjustments to the filling 
equipment sooner. Waiting times have also been decreased because WIP is no 
longer waiting to batch prior to movement. Bulk drug in drums, WIP totes and 
finished goods pallets are all moved individually, and require fewer quantities to be 
106 
moved. The cumulative effects of these changes result in a lead time of 
approximately 2130 minutes which is about a 75% reduction of time. It is important 
to note that this future state finds the time to produce the frrst pallet of finished goods 
inventory. The future state no longer waits to batch the finished goods prior to 
shipping; therefore, this estimate is useful to determine how quickly finished goods 
would be ready to begin shipping if there was flexibility with the customers to 
receive goods in more frequent smaller delivery amounts. 
This future state is based upon the scenario with the lowest throughput time 
from the 8 scenarios tested. This throughput time can be considered a conservative 
estimate. Many of the effects of the suggested improvements to areas of need could 
not be readily quantified or modeled. Many of the other lean techniques discussed 
earlier in the areas for improvement would further impact the lead time. One 
example is implementing quick changeovers to decrease setup and adjustment times 
have been shown to decrease the necessary time by 20-40% (Centers and West, 
2001 ), which could also help XYZ Pharma. While these improvements would be 
qualitative, they could have both direct and indirect impacts on the total throughput 
time of the system. 
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Figure 24. Future State Value Stream Map based on Scenario 4 
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No. of Ops: 1 No. of Ops: 3 No. of Ops: 7 Shipped 
Bring Only what is 1 Shift 3 Shift 3 Shifts Required to Make 1 I-Batch Size: -I Value Added = Batch Batch Size : Batch Size: 381 Min 50 Sec 
Directly to MFG 8771'g 30 ,000Tulles t-417 Boxes -(72 Ct. each) J area L alue Added= 
16% 
379 Min 10 Sec 160 Sec 10 Min I I 3~Q Mia I I 60 Min I I 145 Min 
721 Min 412 Min 316 Min 
6.6 Chapter Review 
This chapter presented the results of the current state ProModel® simulation 
and the theoretical future state simulations. While all of the three factors tested were 
found to be statistically significant, changing the batching rules was found to have 
the greatest effect. Only one of the interactions of the factors was found to be non 
significant, parallel manufacturing and cross training. Interestingly, scenario 4, 
which incorporated cross training methods and a change in the batching rules, 
yielded the lowest simulated throughput time. A future state value stream map was 
created to help visualize the improvements and the specific areas that had been 
changed. 
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Chapter 7 
7.0 Conclusions 
Lean manufacturing techniques should be explored in the pharmaceutical 
industry to improve current systems and utilized early on in the development of new 
systems. This case study represents a number of possible opportunities for specific 
areas of improvement as well as suggesting an overall change in manufacturing 
mindset. The pharmaceutical industry can learn a great deal from outside industries 
where competitiveness is required to ensure solvency. 
7.1 Linking Pharmaceutical Manufacturing to Outside Industries: 
7.1.1 Approach to Manufacturing 
Contract manufacturers of pharmaceuticals only make what is ordered by their 
customers and use a general pull production system. Usually extra finished goods 
are not manufactured or warehoused, due to the chance of expiration, loss of 
contract, or removal from the market. With many of their products having only a 
two to three year expiry period and products spending weeks to months traveling 
through complex distribution chains, especially for larger national retailers, the 
window of opportunity to sell their products is narrow. Also, preprinted tubing is 
shipped by the customer to be filled with product, resulting in a finite number of 
products which can be manufactured, thus limiting the temptation for 
overproduction. 
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While orders are made to meet customer orders, the internal flow of product 
is pushed through the system. This is due to batch processing which results in 
materials being pushed onto down stream machinery. This method then results in 
manufacturing of as much of the order as possible in their shift, which is then 
batched to move to the next process. There is a lack of production leveling which 
results in uneven production of materials. 
7. 1. 2 Quality 
The focus on product quality is extremely high in the pharmaceutical industry 
to avoid potentially fatal and costly defects. While PAT is an emerging resource, 
many tools are used to ensure that the product meets the rigorous specifications 
required to be safe and efficacious. The pharmaceutical industry is in the process of 
moving away from end product testing and toward in process testing which has been 
used for many years by other industries. 
Product quality for pharmaceuticals comes at a price. The pharmaceutical 
industry carries a large amount of inventory "just in case" and face problems other 
manufacturing industries may not. Large quantities are held in inventory for two 
reasons, 1. The average lead time for custom components is 4-6 weeks and for 
materials is 1-2 weeks and a last minute increase in the order size would result in a 
long lead time. Additionally, components from the customer are not purchased and 
may incur the cost of holding which is then build to the customer if held for long 
periods of time and 2. All batches of incoming materials and components are 
quarantined and require identity conformation. Regardless of the size of an 
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incoming order, only one test is required and is regarded as more convenient by 
quality control. Component manufacturers are not willing to change to a more JIT 
approach and experience many similar problems due to their batch mentality. 
Quarantine is not an issue for most other manufacturers and requires an additional 
inventory buffer to ensure that proper quantities of raw materials are readily 
available. With only a small number of capable and reliable specialized 
pharmaceutical component manufacturers, they are able to dictate long lead times 
without losing business. 
7.1.3 Equipment 
cGMP compliance requires many elements that other industries do not face. 
Validated methods for cleaning of equipment and manufacturing areas are important 
to decrease the chance of unsafe levels of contamination from the environment and 
personnel. The cleaning required between products is rigorous in order to decrease 
the chance for cross contamination between products. This results in longer time 
required for setups and changeovers. If setup times are addressed as a problem and 
visual controls are instituted, any significant changes to the physical equipment may 
require validation from the FDA. If the process has undergone validation, the use of 
two parallel machines is acceptable, but must be evaluated carefully due to long 
setup times and cleaning requirements. 
7. 1.4 Facility 
Some production facilities have a "Job Shop" layout, with all formulation 
equipment grouped near each other and products transported in large vats for filling 
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and palletized totes of WIP. A redesigned layout would place all the equipment in 
proximity to each other in order of flow. During formulation, the general area is kept 
clean for manufacturing and is designed for ease of cleanability. While filling 
operations, it tends to generate far more scrap materials. Due to cGMP regulations, 
certain layouts may not be feasible for fear of contamination to the product. An 
improvement to the flow of material within the guidance can still be investigated. 
Another facility problem is the storage of components and chemicals. 
Storage areas for raw material and finished goods can become cluttered due to the 
quarantine process and the large quantities required for batch processing. This is in 
contrast to a JIT system which would remove finished goods upon completion and 
store needed components close to the manufacturing line. 
7.2 Study Limitations 
Every effort was made to accurately capture the current state of 
manufacturing for product X. Data for the model was based on four batches with 
two batches using the older filling machine and two batches using the newer filling 
machine. The future state model data was based on assumptions derived from 
observations and were not data collected after implementation of the suggested 
improvements. This case study does not accurately represent the entire 
pharmaceutical industry, especially some of the larger companies which have greater 
financial resources to investigate lean and alternative techniques. 
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7.3 Future Work 
Further studies using ProModel® simulation software should be conducted to 
improve the process understanding and diagnosis of problems. Future areas of study 
addressing DfM, failure modes effects analysis (FMEA) and design of experiments 
should be addressed. Experimenting with continuous manufacturing equipment 
during the formulation process and process development should be considered, 
especially for large scale and volume products. The methods and findings from this 
study could be tested to see their applicability to product dedicated equipment and 
facilities. 
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Appendix I: Definitions of current value stream map example (US EPA, 2006b) 
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Cycle time 
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Inventory 
Truck sh ipment 
External sources (suppliers. customers. etc.) 
Electronic information flow 
Movement of production material 
Supermarl<st (a controlled imientory of parts 
ithdrawal (pull of materials, usually from a supermar~:et) 
Production kanban (card or device that signals to a process 
hovl' many ofwnatto produce) 
Signal kanban (shO'NS when a batch of parts is needed) 
Ka izen starburst (identifies improvement needs 
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Appendix Ill: ProModel® Simulation- Current State 
........... ., ............ + ........ . + . .. ............. + ..... . ................ + ...... + ..... ........... + ••• 
Format':.ed Listing of Hodel: 
C:\Documents and Set-:ings\uri u.ri\Deskt.053\model\final curren:..HOO 
.............. ., •••• +•• ................ ++• .................... . +•• +• +•• ................. +•' 
Time :Jnit.s: 
Distance Oni t.s: 
Minutes 
Fee~ 
.................... fi•••········································•••+••············· 
Locations 
............................................................................................ 
Na:te Cap Units St.at.s Rules Cost 
------------------------ ----------- --------------- ------------
Marehousinq_ AJ:ea INE" 1 Time Series Oldest, Fir st 
Formula ti on_ Holding_ Area Time Series Oldest, . 
Jones _wrr_ feed 100 1 Ti.lte Series Oldast, 
Jones _cart.oner 10 Ti?te series Oldest, . 
i'allet _Wrapper Ti:e Series Oldest, 
Jones 
-
FGI eo Time Series Olde.st , . 
2 Kalex_ Tims Series Oldest, , 
IW?IA Time Sraries Oldest, 
Kalex_ 1 Time Series Oldest., . 
Delivery_ Truck 12 Time Series Oldest, , 
Cafe 
-
table 20 Time Ser ies Oldes:., . 
Lee _!tattle Tilte Series Oldest, . 
IWilA_l!IP_l!olding 100 1 Time Series Oldest, 
Load Storaqe_Vat_ Tima Series Oldest, , 
Vat_.Eoldino;_A..rea Time Series Oldest., 
Desk QC 
-
Tim~ Series Oldest , 
........................................................................................... 
Entities 
Nama Speed (fpm) S-:at..1 Ccst 
------------ ------------ ------------ ----------- ------------
Aa;v_InqriS1dients_Drum lSO Time Series 
WIF _Totes lSO Time Series 
Finished_Goods _ rr.v-entor y lSO Time Series 
Transfer _Vessel lSO Time Series 
Raw_ Boxed_ Ingredients 150 Time Series 
PALLET FGI 150 Time Series 
-
.................................................................................. 
Path Net-.,,od:s 
................. .................. ......... .......................... ............. ' .............. , .. 
Name Typo T/S Fr cm To BI Dist/Tiin9 
---------------- - --- -------- - ----------- ---- ----------
Oriver_path i'assing Speed 
' 
Digcance Nl N2 Bi S6.1E 
N2 N3 Bi S7. 15 
path_ manufacturer Passin9 Speed 
' 
oiscance Nl N2 Bi 35.66 
Nl NS Bi 215.85 
Nl NE Bi E. SS 
NE ~3 Bi 41.€0 
overvie·..- Passing S~eed 
' 
Cistance Nl N2 Bi 71.9€ 
N4 NS Bi 31. EO 
!11 NS Bi 4. 95 
NS !19 Bi 37 .23 
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Speed Factor 
------------
N9 N!O Bi 10.U 
NlO Nll Bi 13. S4 
Nll Nl2 Bi 18.H 
NS Nl 7 Bi 4.42 
NS N3 Bi 213.3S 
N2 Nl2 Bi 24. 70 
NZ N4 Bi 107 .ZJ 
Nl1 N7 Bi 22B.6S 
Nl7 Nl~ Bi 41.3~ 
Nl4 N7 Bi 1Bo. l6 
NlS N3 Bi S2 .39 
......... , ................. '+' ......................... ' ................... +• .... +• '+ .............................. .-.. 
Interfaces 
................................................................................................................. ., ........... ... 
Net Node Location 
Driver~e-ath Nl Delivery_ Trude 
N2 
N3 
path_ma.nufacturer Nl 
N2 
overview 
NS 
N6 
N3 
Nl 
N2 
N4 
NS 
N7 
N8 
N9 
NlO 
Nll 
N12 
N3 
Nl7 
N14 
N1S 
Warehousing_ Area 
2ormulation _Holding_ Area 
Lee_Kettle 
Farmulation _F.oldir.g_ Area 
Cafe_ table 
Storage_ Vat_ Load 
Vat_ Holding_ Area 
Delivery_ Truck 
Warehousir.g_ Area 
Cormu lat ion_ Hold.inq_At:ea 
Lee_l\ettle 
IWllA 
IWF.A_WIP_Holding 
Jones_ffIP_feed 
Jones_ Cart.oner 
Jcnes_FGI 
Pallet_Wrapper 
Cafe_table 
Storage_Vat_Load 
Va"_ Holding_ Area 
cc_nesk 
.................................................................. ,.. ........ *"'' ......................... . 
Mapping 
............. ' ...................... '+ .......... ' ..... + ..... +·•. +' ..... + ....... + •• + t ..... + ......... ' ...... + ... .. 
Net From To Des~ 
path_ manufacturer Nl N2 
Nl NS 
Nl N6 
overview N2 Nl 
N4 N2 
NS N4 
N7 NE 
N8 N9 
N9 Nl O 
NlO Nll 
Nll Nl2 
Nl2 N2 
Nl7 NS 
NH N11 
N2 N4 
N4 NS 
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N7 NH 
NS N7 
Ni Nl2 
NS Nl7 
S9 NS 
SlO NS 
NU Nl: 
Sl2 Nll 
Nll NH 
NH N1 
NS li3 
,, ••• ' ···-·· ....... ' '*''. ' ............. ' ' ..... ' ........ •·••• ..... ............................ . 
P.escurces 
..................... ' ....... ' ....... ' ............. ' .............. ' ............... " ... ' ............ . 
Ras tnt 
Name Units Stats Search Search Path Motion (;ost 
Manufact~rer By Onit Closest Oldest path_ri:anufacturer Er!;>ty: 150 fpm 
Eoite: Nl Ml: 150 fpm 
Haterial _Sandler_ l By Oni t Clcsest Oldest cverview ~,_f::y: iSO :pm 
Eette: N2 Full: 15) =~Ill 
Material_ ha.ndler _ 2 By :Jnit Clcses: Oldest overview Empty: 15~' =~ 
Hetc.e: N2 Ml: 15) :pm 
Dri ;rer By Unit Clcsss:. Oldest Driver _path Empty: 1s:. !'pm 
Re-me: Nl :Ull: 150 fpm 
(Return) 
Mechanic By ~nit Closest Oldest c-:.•erview !!l!pty: 150 fp!! 
He.rte: N1 :Ull: 150 fpm 
Operator_l By Onit Cl osest Oldest ov&rvie•.i ;)npty: 150 fpm 
Ecime: N1 Full: 150 fpm 
Cperator_2 By Onit Clcssst Oldest cvervis"A Elt;>ty: 150 :pm 
Eou:.e: N10 Ml: 150 fpm 
operator By Unit Clcses: Cl des: cverview Empty: !SO !pm 
Some: N7 :Ull: !50 fpm 
OC: _Inspector By Unit Clcsast Cldes: overview Er,pty: 150 !pz 
RC<~e: Nl5 ;'Jll: !S;J fp:n 
.................................................... ,, ..................................... ' t. 
Processinq 
..................... t ..... . .............................................................. . 
~-rocess 
Entity L<:caticn Operation Blk 0-otput Destination Rule 
Ra'.i _ lnqredien·ts _ Drwa. Celivery_TIUCk llAIT N (. 2, . 3) 
VIEW "loading dock" 
R~• _ lnqredients _Orum Ware!:.ous inq_ Area FIRST 
Raw_ Boxed_ Ir.qredients Delivery_ Truck iiAlT N(.2, .3) Rur _Boxed_ lngredients Marehousing_krea FIRST 
Raw_ Inqrt1:dients _Drum Warehousinq_ Aiea li<UT N(.5, .2) 
VIEW "warehouse" 
Ra<irr _Ingredients_ trum Formulation_ Hclding_ kraa ?IRST 
Raw_Bcxed_Inqtedients Warehousinq_AI:ea li<UT N(.S, .2) Raw_ Bcxed _ Inqredients E'onr:ulatitr:._ Holding_ :..rea FIRST 
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ALL Formulation_Holdinq_Area Accum 4: 
Transfer_ Vessel 
Transfer_ Vessel 
Transfer_ Vessel 
WIP_Totes 
WIP_'l'otes 
WIP_rotos 
l-ee_Ke'ttle 
Storaqe_ Vat_Load 
Vat_F.oldinq_~.rea 
lil!V. 
IW~A _ WIP _F.oldir.g 
Jcnes _ WIP _feed 
Jones_ Cartaner 
Finished_G<xtds_Inventor y Jones_rGI 
VIEW "manufacr.urinq pro::ess• 
Combine 4 
IP S0?2=0 
!KEN 
Ra'.(_ Ingredients_ Drum 
Raa_~xed_Inqredients 
Use Manufacturer for N(e:,10) Wait . l 
S0?2=1 
Ost Manu~acturer to-R N ( ~ SC , 30} 
Transfar_Vessel 
OSE Manufacturer FOR N {120, 30) 
1 Transfer_Vessel 
liAIT ~(3340, 199i) 
Transfer_ Vessel 
IF SO!=J 
TREN 
IJse H~chanic for N(300,SCt) Wait .1 
SUT=l 
Use Operatcr : cir N(495 , 42) 
il.CC\!ln 21 
ac::um -84 
IF StTTl=O TH.EN 
"IP_Totes 
WIP_Totes 
KIP_Tot.es 
OSE ~.echa.,ic for N (2 40 , EO) Wait .1 
SUTl=l 
OSE C~&ra-:cr_l FC..~ N(7,2j or c:".A!ra~or_2 FOR N{7 ,2) 
tee_K~ttle 
Lae_Kettle 
s:orage _'lat_ ~ad 
Vat _ Holding_ Area 
IW!'.A 
Ilr!V'._ WIP _Holding 
Jones_tilC:_feed 
Jones_car:or.er 
Finis!'ted _Goods _In~entory Jones_ FGI 
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FIRST 
FIRST 
P!RST 
FIRST 
tIRST 
FIRST 
E'IRST 
r!RST 
Co=.bine 70 
PAI.LZT_PGI Pallet_ Wrapper 
Palle:._Wrapper USE Natilrial_Har.dl&r_l for N(3, l ) or Haterial_handhr_2 FOR Nt 3, l) 
WAlT ~(14, 3 ) 
PALLET_i'CI 
PA!.LET_E'GI 
Entity 
Wa rehou9in9_.:...rea 
Delivezy_Tn:ck 
Azrivals 
PAf.LETJGI 
Accum 6 
USE OC_lns~•ctor fer N (30, Sj 
Wai~ N{22e5, 1200) 
PAf.LET_!'GI 
?All.E1'_:-Gl 
Loca ticr: Qty Each Fir5t Time C<:currences Frequency Lcgic 
Raw_Ingredients_Orum Del i?er 1_Truck 6 
Ra·i1_Boxed_Inc;red.ients Deli.-sry_Truck 6 
... . .... ...... . t .... ........ t ..... .... .... ...... .... . . . ...... .. ..... . t . ..... . ........ .. . ....... .. t ....... . t .... 
Shi ft h.ssiqn?lient.s 
Locat.ior..s. . . R•sources ... Shift Fi las ... Priori tbs ... Disable Logic ... 
ID 
Attl 
Uri'ler 
Mar.u!•ctuzer 
Mechar.ic : 
C: \COc;.ments and ~e-:tir.q.s\uri 99, 39, 99, 99 Ne-
Mat.a rbl_Ha.r.dler_l: C:\Oocu::i.entt ,u:.d Se:.tinq&\ uri 99, 99, 99 , S~ No 
Oper•tor l 
cperator 
Cperator_2 
Hat.erial_h.ar..dler_2: 
C: \Ccc;ments and Se:.t.ir..qs\uri 99, SS, 99, 99 No 
C:\Dccu::i.ents a.r.d Settinqs\ Uii 99, 99, 99, 99 No 
Attrib'.ltas 
Type Classificaticn 
Entity 
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Warehcusinq_J..rea 
Oeli very _'?ruck 
£XU 
FIRST 
FIRST 
FIRST 
FIRST 
............................................................................................ , 
IO Type Initial value St.ats 
SOT Integer Time Series 
SOTl Inteqer c Time Seriss 
SOT2 Integer c Time Seriss 
'larl Int.a1;p1r 0 Time Series 
..................................................... ,., .................................................................. . 
Arrays 
................................................................... ............................... 
IO Di:tensions Type Import. File £xport File Disable Persist 
Arrl 
ID Text 
Macl 
IO Type 
Subl None 
IO 
(null) 
(null) 
(null ) 
Shift 
Sh ift 
Shift 
Int.eqer None Ne 
Macros 
subrout.ines 
Parameter Type Log ic 
External Fi las 
File Name 
C: \ Docw:ter.t.s and Settir.qs\ uri uri \ M/ Document.s \ dsn s h ift 2.sft 
C: \Documents and Set.tin;s\uri uri \ Hy Dc::~ents\der. shi~"t 3. sft. 
C: \ Oocumer.":s u:.d Set.t.ings\u ri uri\My DC'cumer.t.s \ dan shift.sft. 
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Prompt 
Appendix IV: Pro Model® Simulation- Future State 
•••••••••••••••••••••••••••••••• '+ •• + •••••••• ++ •• + •••••••••••• + .................. . . 
Formatted Listing of Model: 
C: \ Documents and Settinqs\uri uri \Desktop\z:ic;del \wcrking fut.ure new .MOO 
.................................................................................. 
Ti.me Or.its: 
Distance Units: 
Minu<;es 
!'eet 
..................................................................................... 
Locations 
Name Cap Onits Stats Rules Cost 
Receiving_ Area IN? 1 Time Series Oldest, . Firs:. 
Formulaticn_Hclding_AI:ea Time Series Oldest, . 
Jones_ffIP_feed 100 rime Series Oldest. , 
Jones_Cattoner 10 1 Time Series Oldest, 
Pallet_Wrapper 1 Time Series Oldest, 
Jones_FGI eo Ti.me Series Oldest, . 
~alax_2 Time Series Oldast, . 
IWllA Time Series Oldest, . 
Jlalex_l Tia!e Series Oldest, . 
L'eli;rery_Truck 12 Time Series Oldest, . 
Cafe_table 20 Till!e Series Oldest, 
I.ee_Kettle Time Series Oldest, 
IWAA_ llIP _Holctin; 100 'l'i!!!e S6ries Oldes:., . 
Storaqe_ Vat_Load Time Series Oldest, 
Kalex_Wip_Pallet 20 Tir.e S&ri&s Oldest, 
OC_Desk Time Series Oldest , 
Hopper 21 Tiine Series Oldest, 
.................................................................................................... 
Entities 
........................................................................................ 
Name Speed (fpm) Stats Cost. 
------------------------ ------------ ----------- ------------
Raw_ Ingradisnts _ Dru:m 150 Time Series 
WIP_Totes 150 Time Series 
Finished_ Goads_ Inventory 150 Time Series 
Transfer _Vessel 150 Time Series 
Ra·..,_ BC'xed _ Inqredients 150 Time Series 
PALLET _FGI 150 Time S&ries 
Bulk_Droq_WIP_ l 150 Time Series 
........... •<fl ................... t ...... t' •• ' •••••• '" •••• ' ......... t ...... t' •• ' +.' •• t ••• 
Path Natvor:u 
•••••••••••••••••••• ••11 ••··· •••• ' •••••••••••••••••• ' ••••••••• ,., •.• ,' ............. . 
Name Type TIS Fro.n To BI Oist/Tima 
-------·-------- ---·-----·- ---- --- ·-----· -- --·--·----
Driver_path Passing Speed 
' 
Ois:.anc9 Nl N2 Bi 56. lE 
~2 N3 Bi e1 .1s 
path_manufacr.urer ?assinq Speed 
' 
Cistanca Nl N2 Bi 35.H 
Nl ~s Bi 21s. es 
Nl Ne Bi t. 68 
o7er7iew Passing Speed 
' 
Cistance Nl ~~2 Bi 71. 56 
~H NS Bi 31. 60 
N7 NB Bi 5.53 
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Speed !'actor 
----·--·--·-
NS NS Bi 37 .2 3 
NS NlO Bi 10.41 
NlO Nll Bi 13 .e! 
Nll N12 Bi l< .H 
NS N17 Bi 4.86 
NS N3 Bi 213. 3S 
N2 N12 Bi 24. 70 
N2 N4 Bi 107 .23 
Nl7 N7 Bi 228. 6S 
Nl7 N14 Bi 255 . S3 
Nl4 NlS Bi 6. 75 
NlS N9 Bi 62 . 35 
NlS N3 Bi 51. 99 
N7 Nl9 Bi ll.53 
Nl9 NH Bi 13. 40 
........................................................................... ••·+ ..................... + ...... . 
Interfaces 
............................. . ............ *++i:i"• +• ...... ........................... T+ ......... I ... ........... . . 
Net Node location 
Oriver_path Nl Deli vary_ Truck 
N2 
N3 
path_manufacturer Nl 
N2 
NS 
N6 
overview Nl 
N2 
N4 
NS 
N7 
NS 
N9 
NlO 
Nll 
N12 
N3 
N17 
N14 
NlS 
N18 
N19 
RJ?cei ving_ Area 
Formulation _Holding_ Area 
Lee_Kettle 
Form-..i la tion _Holding_ ~..rea 
Cafe_table 
Storage_Va":_l-0ad 
Deli ver y_ Truck 
Receiving_ Area 
Formula ticn _Hol ding_J...rea 
Lee_Rettle 
HOO\ 
IWK.;_1'1IP_Holding 
Jones_WIP_feed 
J ones_ Cartoner 
Jones_~! 
Pallet_ Wrappe r 
Ca fe_table 
Seoraqe _Vat_ Load 
Kalex_ 2 
Ka1ex _Wip _Pal let. 
OC_Oes< 
hopper 
................... • ·• ....... + .................. +• ........... ..... . +• ...... +• ............ + ....... +• '+. ** ........... .. 
Mapping 
ii*** .............. ¥-t•+ • +t • + ....... +• ............ + 6 6'+• +·•• ** ...... +• ...... +••+ 6 ...... +• ............. I ..... 6Y6 ..... "'*' 
Net From To Dest. 
path_ manufacturer Nl N2 
Nl NS 
Nl N6 
overview N2 Nl 
N4 NZ 
NS N4 
N7 Nf 
N8 N9 
NS !11 0 
NlO Nll 
Nll Nl2 
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Nl2 N2 
Nl7 NS 
NB Nl9 
NlS N9 
Nl9 N7 
N2 N4 
N4 N5 
N7 N11 
SS !11 
Sl5 !114 
N2 Nl2 
NS Nl7 
N9 NS 
YlO N9 
Nll NlO 
tn2 !Ill 
Nl7 !11 
N5 !13 
Nl !119 
!119 NH 
N9 NlS 
NH N15 
........ +•• .......................... , ...................................................... . 
P.escurces 
..................................................... '"'*" ••••• , ••• +• .......... ++, ••• •· ... . 
Res Ent 
Name onits Stats Search Search ~ath Hot ion Cost 
Manufacturer Ey !Jnit Closes4; Oldest ~ath _ :tanufactur&r Empty: 150 :p:a 
Horc.e: Nl Full: lSJ fpn 
Material _Randler _ 1 By Onit Clcsest. Oldest O"IEI\"iew !:mpty: 150 :pm 
Some: N2 Full: 150 fpm 
~terial _handler_ 2 By Unit Clo sen Oldest overview Empty: 150 fpm 
Home: !12 FUll: 150 fpm 
Driver By Unit Closest Oldest llriver_path Empty: 150 fp:n 
Bc.1te: !11 Full: 150 fpm 
(Re:arn) 
Mechanic By Unit Clcsest Oldest cver-.rie·.., Emp:y: 150 ~P= 
!ica:e: N7 Full: 150 fpm 
Mechanic_2 By Onit Clo9est Oldes: cverview !:mpty: 150 fpm 
Home: N1 "'11: 150 fpm 
Operator_! 10 By Unit Closes: Oldest cverview !l!:pty: 150 !pm 
?.ein:e: ITT 1'.lll: 150 :pm 
Operator_2 1~ By Unit Clos&so:. Oldest cver\'ie-,,; ;Jtpty: 150 !pn 
?.c·me: NlO 1'.lll: :S:i ~pm 
OC _ lnspectcr By t?nit Closest Oldest cver1ieOi1 Empty: 150 :Fm 
Hotte : NlS cull: lSO fpm 
................... ••+ ..... + ..... ••+ ..... ++• •• ••+ .......... ••+• •••••••• •++• .................. . 
?rocessinq 
........ '' .... ' .................. ' .................................. ..... ' ...... ''. 
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Enti~y 
Rav_ Ir.g:redien:.s _ Drll!D 
Raw_ Boxad _ Inqredients 
AL~ 
ALL 
Bulk_Druq_WIP_l 
Bulk_Dr~g_Wll' _l 
Bulk_Drug_ WIP _ l 
Bulk_Drug_WIP _l 
lflP_Totes 
Bulk_ Drug_fll P _ I 
'iJIP_Totes 
WlP_Totos 
WIP_Totes 
Lcca:.ion Operaticn 
Delivery_ Truck ii;JT N( .2,. 3) 
VIEW "lo•ding dock" 
Ueli·1ary_Truck WAIT N(.L, . 3) 
ii.a '~_ Ingredients_ Drum 
Raw_ Boxgd _ Ing!edients 
Destinaticn Rule 
E'onr.ulat i on_Hol ding_Ana FIRST 
rormulaticr._Holding_rtrea FIRST 
Fcrmulati~n_Eolding_Area Accum 4 
L-iie_Kettle 
Stcraqe _Vat_ L-cad 
Hc;:per 
F.cpper 
Ifl!IJI. 
IWM_iUP_Holdini; 
JC.alex_t 
llalex_ ffip_Pallet 
J ones_WIP_faed 
Jo!'les _ Car tcnar 
'IIEW ":r.anuhcturinq process• 
Combine 4 
I:' SU1'~=0 
?F.£N 
!\ail_ Inqredients _ Dri!m 
Rar.1 _Boxed_ Ing.redie=i.ts 
Osa N3nufac;urer !er N (S:, 10) 
SUTL=l 
Bulk_Drug_li!P_l 
OSE Manufacturer FOR N (30, 5) 
If SUT=O 
Tf.EN 
3ulk_Drcg_tHP _1 
3ul:< _Drug_ IHP _ 1 
31.01'.t_Oruq_fi!P _ l 
B\:lk _ On:g_ K!P _ 1 
lee_Ke:tle 
LeE:_Ke:;:le 
S:oraqe _Vat_ toad 
liop~er 
HO~f.C! 
Jlll<.; 
Kalex_2 
'Jse Mechanic for N(3C•0,90) or Hechanic_2 for N(3CC, 90) 
SU?=l 
Qse O~&ra:or_l fo r N(E.1,2) or Cperatcr_l. for S(6.1,2j 
IF SOT3=0 
TF.EN 
H'lP_TOtllS 
Jl'IP_Totes 
JWJ(A_WJ? _Holding 
Jones_KI?_feed 
Use Mechanic for N(Hl,30) or Mechanic_2 for N(lU , 30) 
S013=1 
Use 01=era:cr_l fer N(12,2 . S) or Cpera:o::_~ fC'r N(12 , 2.S) 
FIRST 
;'!RST 
?IRST 
?IRST 
FIRST 
HOS? 
HOS? 
FIRST 
FIRST 
1 tflP _ Tot~s Kalex _lii~ _ ?allet FIRST 
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WIP_To:5s 
tHP_TOt9S 
Jones_ilP_feed 
Jonas_ Cartone r FIRSr 
IF SO!l=O T!LPN 
OSE mechanic for N(H0,60) or Hed.anic_2 fC!r N(2 4C,60) 
Strrl=l 
USE eperator_l FOR N(1,2 ) or Opara.tor_L FOR N(!,2) 
Finished_ Geods _ Inve..'\tory Jones_ FGI 
Fidshed _Goods_ Inver:tory Jones _FGI combine 70 PALLET_FGI Pallet_ Wrapper 
PA!.l.ET _ FGI Palle: _ wu.pper iJ SE Ma:srial_?.arr.dlsr_ FOR N(3,l )or Ha:erial_Handler_2 FCR N(3,1) 
WAIT N(!4, 3) 
PF.LLET _ FGI Recei ·1inq_ ~.rea 
PALLET_l'GI Delivery_ Truck 
?ALLET_FGI 
nai' N(IZQ, lC) 
Use c:_Inspectcr for N(S, 1) 
PF.l:LET _ FGI 
?ALUT_FGl 
............. +• ................ ,. .......... + .................... •It ............. '** ........ • It•* ..... + 
Arrivals 
.................................................... , ....................................... . 
Entity Loca:ion Qty Each Firs':. Time occurrences Frequency Lcqic 
Ra·,_ Ingredients_ Drum Deli '1ery_ Truck 2 
Ra..,_ Bcxed _ lnqredients DBli very_ Truck 2 
......................... ' ..................................................................... . 
Shift Assiqrutents 
....................................... -.. .............................................................. .. 
Locations. . . Resources ... Shift Files ... Pricrities ... Disable toqic ... 
triver 
Kanu:acturer 
C:\D-cCUlter.ts and Set:inqs\uri 99,!"9,99,S9 No 
t'.aterial_Handler_l C: \ Dccun:ents and Set:ings\uri 99, 99, 99, 99 No 
Operatcr_l 
?'.anufacturer 
Cperator_2 
Material_ ha.ndler _ 2 
Mechanic_2 
C: \OOCUll!.ents and Setdnqs\ uri 99,9S,99,9S ~o 
•••••• ' ............ ' ...... ' ••••• •++•' ........ •·++•• •••••• , ..................... ' , ..... ' •••• 
Attributes 
....................................................................... ' ......................... .. 
ID TYJ'e Classificaticn 
Attl lnteqer Entity 
....................................................................................... 
Variablos (qlobal) 
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Receh·ing_Mea 
Deli ".lery_ Tnck 
EY.IT 
FIRST 
f!RST 
FIRST 
rIRST 
FIRST 
................ ******•••···· ••• _ ........................................... ··•••*****"'*" 
ID 
SOT 
SOTl 
SOT2 
SOT) 
Type 
Ir.teqer 
Integer 
rnteg•r 
Integer 
Initial value S'tats 
Time Series 
0 Time Series 
0 Time Series 
Ti.mt Series 
Arrays 
* ................. ' ................................ *** ...................... ' ....... *** •• ** 
ID Dimensions Type Imf~rt File Export File Disable Persist 
Integer None No 
••• •·+•• ................... ' •••• ' * ....... •+••• ...................................... '++t .......... ... 
Macrcs 
•+t+ * *. ++• + + +*+* t • *** + t '++ .. • **"'** t * •++• +' •T+ t + t Y+ + t +tr++•+* ....... * t + *** t 1'I + i-+<t t + .... Ir t 
ID Text 
Ma cl 
**'" ..... ' .............. *" ••••• '"'**' •••••• ' .................. ' ....... •+i: •• ' ••••••• •• •• '. 
Subro-.itines 
............. '"*• .• l+••• •i-+·•· .................. **"''. ''"*••' ......................... '**'''' ...... . 
ID Type ?ara:r.ster Type Logic 
Subl None 
........... ' ......... , ......... , ....... ,' ....... , ........ ,, * ............... ,' .............. , ....... ' ....... , ' ...... ' .... 
External Files 
' ...... ' ••••• ' ............ ' ••••• ' ..... , '"***' ...... , ........... '' ................... ,' ••• 
ID 
(null) 
(null) 
(null) 
Shift 
Shift 
Shift 
File Name 
C: \ Documents and Settin9s\uri uri \My Dccuments\den shift 2. sft 
C: \ Docv.ments and Settinqs\ uri uri \My OGcmr.ents \ den shift 3.sft 
c: \ Docwr.sr .. ts and Settinqs\uri uri\My Dcc:uments\dan shift. sft 
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Prorrpt 
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